CURRICULUM VITAE: WILLIAM J. JUSKO

Address: February 15, 2023

Department of Pharmaceutical Sciences, Pharmacy Building 404
School of Pharmacy and Pharmaceutical Sciences
State University of NY at Buffalo, Buffalo, NY 14214-8033
Phone (716) 645-2855; FAX (716) 829-6569 E-MAIL: wjjusko@buffalo.edu
ORCID No. 0000-0003-4027-0550

Weblinks:

http://www.webofknowledge.com/ Jusko, W
http://pharmacy.buffalo.edu/departments-offices/pharmaceutical-sciences.html
http://www.researcherid.com/rid/G-4885-2015
https://www.linkedin.com/pub/william-jusko/33/aa7/825
https://www.facebook.com/william.jusko

Education:

Salamanca High School, NY	1956-1960 Secondary Education
State University of New York at Buffalo	1960-1965 B.S. Pharmacy
State University of New York at Buffalo	1966-1969 Ph.D. 1970

Appointments:

State University of New York at Buffalo, School of Pharmacy and Pharmaceutical Sciences,
Department of Pharmaceutical Sciences

SUNY Distinguished Professor	Nov 2008 - present
UB Distinguished Professor	April 2007 - Nov 2008
Professor	April 1977 - Apr 2007
Chair, Department of Pharmaceutical Sciences	Jan 2001 – May 2016
Director, Center of Excellence in Pharmacokinetics and Pharmacodynamics	Dec 2005 -present
Vice-Chairman, Department of Pharmacy	April 1984 - Oct. 1986
Director, Doctor of Pharmacy Program	Sept. 1981 - Aug. 1986
Associate Professor of Pharmaceutics	March 1974 - April 1977
Assistant Professor of Pharmaceutics	Aug.1972 - March 1974

Millard Fillmore Hospital, Buffalo, NY Director, Clinical Pharmacokinetics Laboratory	Aug. 1972 - Sept. 1981
Mario Negri Institute for Pharmacological Research, Milan, Italy, Visiting Scientist	Sept. 1978 - June 1979
Veterans Administration Hospital, Boston, MA Clinical Pharmacology Section, Research Pharmacologist	Sept. 1969 - July 1972
Boston University School of Medicine Department of Pharmacology, Assistant Professor of Pharmacology	June 1970 - July 1972
Boston Collaborative Drug Surveillance Program Boston University Medical Center, Research Associate	Sept. 1969 - July 1972
State University of New York at Buffalo Dept. of Pharmaceutics, Research Assistant	Sept. 1966 - Aug. 1969

Soby's Pharmacy, Buffalo, NY, Pharmacist March 1966 - June 1968

Children's Hospital of Buffalo, NY, Hospital Pharmacist Sept. 1962 - Feb. 1966

Consultant:

Council for International Exchange of Scholars (Fulbright Scholar Program)
Medical Sciences Award Committee, 1980-84
National Institutes of Health, Pharmacology Study Section, 1980-84, 1997-01; Others: at present
Food and Drug Administration, CDER, Clinical Pharmacology Advisory Committee, 1999-2007
Various pharmaceutical companies, 1978-present

Awards and Honors:

NIH Predoctoral Research Fellowship, 1966-1969.
Fulbright-Hays Award to Mario Negri Institute, Milan, Italy, 1978-1979.
Fellow, Academy of Pharmaceutical Sciences, 1980.
Rorer Award, Second Best paper in: Am. J. Gastroent., 1980, (Ref. 116).
Fellow, American Association for the Advancement of Science, 1985.
Fellow, American Association of Pharmaceutical Scientists, 1986.
Rawls-Palmer Award, Am. Soc. Clinical Pharmacology & Therapeutics, 1987.
Doctor Honoris Causae, Jagiellonian University, Krakow, Poland, 1987.
Russell R. Miller Award, Am. College of Clinical Pharmacy, 1988.
Citizen of the Year (Health/Medicine), Am-Pol Eagle, Buffalo, NY, 1987
Distinguished Service Award, Am. College Clinical Pharmacology, 1989.
Fellow, American College of Clinical Pharmacology, 1989.
Faculty Exchange Scholar, State University of New York, 1990
Kosciusko Award, General Pulaski Assn. of Niagara Frontier, 1996
Research Achievement Award in PPDM, AAPS, 1998
John G. Wagner Lectureship, University of Michigan, 1999
Sustained Achievement Award, University at Buffalo, 2002
Roland T Lakey Award Lecture, Wayne State University, 2003
Chancellor's Award, University at Buffalo, 2003
ISI Most Highly Cited List in Pharmacology, 2003
MERIT Award, National Institutes of Health, 2005-2015
Volwiler Research Achievement Award, Am Assn Colleges of Pharmacy, 2005
Swintosky Distinguished Lecturer, University of Kentucky, 2006
Paul Ehrlich Magic Bullet Lifetime Achievement Award, Germany, Oct 2008
AAPS Meritorious Manuscript Award, 2008 (Ref. #469)
Leadership Award, American Society of Pharmacometrics, 2011
Distinguished Investigator Award, Am College of Clinical Pharmacology, Sept 2012
ASCPT Sheiner-Beal Pharmacometrics Award, March 2013
Collegium of Eminent Scientists, Kosciuszko Foundation, 2015
Doctor Honoris Causae, University of Paris Descartes, Sept. 2015
Fellow, International Society of Pharmacometrics, Oct. 2016
ASCPT/FDA William Abrams Lecture Award, May 2017
ASCPT Oscar B. Hunter Career Award in Therapeutics, March 2018
Lewis B. Sheiner Pharmacometrics Award, ISoP, Oct. 2019
AAPS Distinguished Pharmaceutical Scientist Award, Oct. 2020

Memberships:

American Association of Pharmaceutical Scientists (1986-present)
American Association of Colleges of Pharmacy (1972-present)
American Association for the Advancement of Science (1970-present)
American Society for Clinical Pharmacology and Therapeutics (1976-present)
American Pharmaceutical Association (1962-2012)
American Society for Microbiology (1975-1994)
American Society for Pharmacology and Experimental Therapeutics (1974-present)
Kappa Psi Pharmaceutical Fraternity (1962-1965)
Rho Chi Pharmaceutical Honor Society (1968)
American College of Clinical Pharmacy (1980-2009)
Federation Internationale Pharmaceutique (1980-2009)
American College of Clinical Pharmacology (1989-present)
European Federation for Pharmaceutical Sciences (1999-2009)
American Society of Pharmacometrics (2011-present)

Listings:

American Men and Women of Science, Who's Who (various venues)

Editorial Boards:

Journal of Pharmaceutical Sciences, 1976-81, 1992-2001
Antimicrobial Agents and Chemotherapy, 1978-1989
Biopharmaceutics and Drug Disposition, 1980-present
Journal of Pharmacokinetics and Pharmacodynamics, 1982-2005
Developmental Pharmacology and Therapeutics, 1980-1982
Drug Intelligence and Clinical Pharmacy, 1982-1987
Clinical Pharmacology and Therapeutics, 1986-2014
Journal of Clinical Pharmacology, 1993-present
American Journal of Therapeutics, 1994-present
Pharmaceutical Research, 1995-1997; Board of Consulting Editors, 2006-2014
Pharmacotherapy, 1995-2002
Journal of Pharmacology and Experimental Therapeutics, 1999-2015
Drug Metabolism and Pharmacokinetics (Japan), 2002-present
Open Access Bioinformatics, March 2009- present
Editor-in-Chief: Journal of Pharmacokinetics and Pharmacodynamics, 2005-2019
CPT: Pharmacometrics & Systems Pharmacology, 2012-2017
Current Pharmacology Reports, 2014-present

Other:

Registered Pharmacist in New York State (License No. 25534, March 1, 1966).
Laboratory Director in Toxicology, Certificate of Qualification No. 588, New York State Department of Public Health (Issued August 13, 1973).

Patents:

1. Benincosa L and Jusko WJ, Novel Method of Treatment, Patent No. WO 00/27341 (May 2000).

Publications:

1. Levy G, and Jusko WJ, Effect of Viscosity on Drug Absorption, J. Pharm. Sci. 54: 219-225 (1965). PMID: 14293807
2. Levy G., and Jusko WJ, Factors Affecting the Absorption of Riboflavin in Man, J. Pharm. Sci. 54: 285-289 (1966). PMID: 5960174
3. Levy G and Jusko WJ, Apparent Renal Tubular Secretion of Riboflavin in Man, J. Pharm. Sci. 55: 1322 (1966). PMID: 5969798

4. Jusko WJ, and Levy G, Absorption, Metabolism, and Excretion of Riboflavin-5'-Phosphate in Man, J. Pharm. Sci. 56: 58-62 (1967). PMID: 6030496
5. Jusko WJ and Levy G, Effect of Probenecid on Riboflavin Absorption and Excretion in Man, J. Pharm. Sci. 56: 1145-1149 (1967). PMID: 6049701
6. Levy G and Jusko WJ, Case History of a Pharmaceutical Formulation Failure, Clin. Pharmacol. Ther. 8: 887-889 (1967). PMID: 6072698
7. Jusko WJ and Levy G, Plasma Protein Binding of Riboflavin and Riboflavin-5'-Phosphate in Man, J. Pharm. Sci. 58: 58-62 (1969). PMID: 5765837
8. Levy G, Gibaldi M, and Jusko WJ, Multicompartment Pharmacokinetic Models and Pharmacologic Effects, J. Pharm. Sci. 58: 422-424 (1969). PMID: 5787438
9. Jusko WJ, Ph.D. Thesis, The Absorption, Distribution, Metabolism, and Elimination of Riboflavin in Man. State University of New York at Buffalo (1970). Dissertation Abst. 31: 71-6083 (1971).
10. Jusko WJ, Levy G, Yaffe SJ, and Gorodischer R, Effect of Probenecid on Renal Clearance of Riboflavin in Man, J. Pharm. Sci. 59: 473-477 (1970). PMID: 5440673
11. Jusko WJ, Rennick B, and Levy G, Renal Excretion Kinetics of Riboflavin in the Dog, Am. J. Physiol. 218: 1046-1053 (1970). PMID: 5435402
12. Jusko WJ, Levy G, and Yaffe SJ, Effect of Age on lntestinal Absorption of Riboflavin in Humans, J. Pharm. Sci. 59: 487-490 (1970). PMID: 5440675
13. Jusko WJ, Leonards JA, and Levy G., Riboflavin Distribution and Elimination in Two Functionally Anephric Human Patients, J. Pharm. Sci. 59: 566-567 (1970). PMID: 5440692
14. Jusko WJ and Levy G, Pharmacokinetic Evidence for Saturable Renal Tubular Reabsorption of Riboflavin, J. Pharm. Sci. 59: 765-772 (1970). PMID: 5463652
15. Jusko WJ, Khanna N., Levy G, Stern L, and Yaffe SJ, Riboflavin Absorption and Excretion in the Neonate, Pediatrics 45: 945-949 (1970). PMID: 5422117
16. Jusko WJ, Levy G., Yaffe SJ, and Allen J, Riboflavin Absorption in Children with Biliary Obstruction, Am. J. Dis. Child. 121: 48-52 (1971). PMID: 5539814
17. Jusko WJ, Fluorometric Analysis of Ampicillin in Biological Fluids, J. Pharm. Sci. 60: 728-732 (1971). PMID: 5125772
18. Jusko WJ, Pharmacodynamics of Chemotherapeutic Effects: Dose-TimeResponse Relationships for Phase-Nonspecific Agents, J. Pharm. Sci. 60: 892-895 (1971). PMID: 5166939
19. Lewis GP, Jusko WJ, Burke CW, Graves L, and the Boston Collaborative Drug Surveillance Program, Prednisone Side-Effects and Serum-Protein Levels: A Collaborative Study, Lancet ii: 778-781 (1971). PMID: 4106604
20. Jusko WJ, Lewis GP, and Dittert LW, Integral Coefficients of Multicompartment Pharmacokinetic Models: Application to Chemotherapy, Chemotherapy 17: 109-120 (1972). PMID: 5046835
21. Jusko WJ, and Lewis GP, Precaution in Pharmacokinetic Evaluation of Ampicillin Precursors, Lancet i: 690-691 (1972). PMID: 4125194
22. Jusko, W.J., and Lewis, G.P., Effect of Hepatic Disease on Liver Flavin and Protein Levels, Am J Clin Nutr 25: 265-268 (1972). PMID: 5011906
23. Cohen JL, Jao JT, Jusko WJ, Pharmacokinetics of Cyclophosphamide in Man, Brit. J. Pharmacol. 43: 677-680 (1971). PMID: 5157730
24. Lewis GP, Jusko WJ, Coughlin L, and Hartz S., The Contribution of Cigarette Smoking to Cadmium Accumulation in Man, Lancet i: 291-292 (1972). PMID: 4109933
25. Wizwer P, Lewis GP, Jusko WJ, and Slone D, A New System For Drug Ordering, Dispensing and Administration in Hospitals, Am. J. Hosp. Pharm. 29: 28-29 (1972). PMID: 5021507
26. Jusko WJ and Gibaldi M, Effects of Change in Elimination on Various Parameters of the Two-Compartment Open Model, J. Pharm. Sci. 61: 1270-1273 (1972). PMID: 5050376
27. Wizwer P, Lewis GP, Jusko WJ, and Slone D, System Records Drug Orders, Drug Effects, J. Am. Hosp. Assn., 16: 86-94 (1972). PMID: 5055143
28. Jusko WJ, Pharmacodynamic Principles in Chemical Teratology: Dose-Response Relationships, J. Pharmacol. Exp. Ther. 183: 469-480 (1972). PMID: 4636387
29. Jao JY, Jusko WJ, and Cohen JL, Phenobarbital Effects on Cyclophosphamide Pharmacokinetics in Man, Cancer Res. 32: 2761-2764 (1972). PMID: 4678592
30. Jusko WJ, and Lewis GP, Comparison of Ampicillin and Hetacillin Pharmacokinetics in Man, J. Pharm. Sci. 62: 69-76 (1973). PMID: 4630199
31. Jusko WJ, Lewis GP, and Schmitt G, Ampicillin and Hetacillin Pharmacokinetics in Normal and Anephric Subjects, Clin. Pharmacol. Ther. 14: 90-99 (1973). PMID: 4345622
32. Lewis GP, Jusko WJ, Coughlin LL, and Hartz S, Cadmium Accumulation in Man: lnfluence of Smoking, Occupation, Alcoholic Habit, and Disease, J. Chron. Dis. 26: 717-726 (1973). PMID: 4648516
33. Jusko WJ, Pharmacokinetic Principles of Pediatric Pharmacology, Pediatr. Clin. North Am. 19: 81-100 (1972). PMID: 5049220
34. Jusko WJ, Pharmacokinetic Principles in Chemical Teratology, Proc. Europ. Soc. Study Drug Toxicity 14: 9-19 (1973).
35. Jusko WJ, The Bioavailability of Drug Products: Ampicillin APhA Pilot Project on Bioavailability, Am. Pharm. Assn., pp. 19-23 (1973).
36. Jusko WJ, A Pharmacodynamic Model for Cell Cycle-Specific Chemotherapeutic Agents, J. Pharmacokin. Biopharm. 1: 175-200 (1973).
37. Jusko WJ, Gretch M, and Gassett R, Precipitation of Diazepam from Intravenous Preparations, JAMA 225: 176 (1973). PMID: 4740282
38. Jusko WJ, The Clinical Status of Predictive Pharmacokinetics, in: "Regulation and Control in Physiological Systems", A.S. Iberall and A.C. Guyton, editors, 1973, Instr. Soc. of America, Pittsburgh, pp. 57-60.
39. Szefler SJ and Jusko WJ, Decreased Volume of Distribution of Digoxin in a Patient with Renal Failure, Res. Comm. Chem. Path. Pharmacol. 6: 1095-1098 (1973). PMID: 4760884
40. Jusko WJ, Rapporteur: in: "Pharmacology and Pharmacokinetics", T. Teorell, R.L. Dedrick, and P.G. Condliffe, editors, Plenum Press, New York (1974), pp. 312-313, 336-337, 348-349, 366-368.
41. Jusko WJ, Szefler SJ, and Goldfarb AL, Pharmacokinetic Design of: Digoxin Dosage Regimens in Relation to Renal Function, J. Clin. Pharmacol. 14: 525-635 (1974). PMID: 4430731
42. Jusko WJ and Weintraub M, Myocardial Distribution of Digoxin and Renal Function, Clin. Pharmacol. Ther. 16: 449-454 (1974). PMID: 4414761
43. Jusko WJ, Interpretation of Cell Proliferation Curves Using a Two-Compartment Cell Model, Math. Biosci. 21: 31-37 (1974).
44. Gretch M, Jusko WJ, Interpretation of Drug Binding Changes in Relation to Protein Concentration, Br J Anesth 46: 545 (1974). PMID: 4458779

45. Jusko WJ, Clinical Pharmacokinetics of Digoxin, in: "Clinical Pharmacokinetics - A Symposium", G Levy, editor, APhA., Academy of Pharmaceutical Sciences, Washington, 1974, pp. 31-43.
46. Jusko WJ, Pharmacokinetic Management of Antibiotic Therapy, in: "Clinical Pharmacokinetics - A Symposium", G.Levy, editor, A.Ph.A. Academy of Pharmaceutical Sciences, Washington, 1974, pp. 111-127.
47. Jusko WJ, Conti DR, Molson A, Kuritzky P, Giller J, and Schultz R, Digoxin Absorption from Tablets and Elixir: The Effect of Radiation-Induced Malabsorption, JAMA 230: 1554-1555 (1974). PMID: 4479663
48. Danish M, Schultz R, and Jusko WJ, Pharmacokinetics of Gentamicin and Kanamycin During Hemodialysis, Antimicrob. Ag. Chemother. 6: 841-847 (1974). PMID: 4451356
49. Jusko WJ, Slaunwhite WR, and Aceto T, Partial Pharmacodynamic Model for the Circadian-Episodic Secretion of Cortisol in Man, J. Clin. Endocrinol. Metab. 40: 278-289 (1975). PMID: 163972
50. Garrettson LK and Jusko WJ, Diphenylhydantoin Elimination Kinetics in Overdosed Children, Clin. Pharmacol. Ther. 17: 481-491 (1975). PMID: 1122689
51. Lalka D, Jusko WJ, and Bardos TJ, Reactions of 2,2-Dimethylaziridine-Type Alkylating Agents in Biological Systems. II. A Comparative Pharmacokinetic Study in Dogs, J. Pharm. Sci. 64: 230-235 (1975). PMID: 236372
52. Jusko WJ, Factors Affecting the Pharmacokinetics of Some Psychoactive Drugs, Proc. of the Symposium: Clinical Pharmacology and Toxicology of Psychoactive Drugs, E.M. Sellers, ed, Addict Research Found, Toronto, pp.55-72 (1975).
53. Jusko WJ and Levy G, Absorption, Protein Binding, and Elimination of Riboflavin, Chapter 4 in Riboflavin, Rivlin R.S., editor, Plenum Press, New York, 99-152 (1975).
54. Jusko WJ, Gerbracht LM, Golden LH, and Koup J., Digoxin Concentrations in Serum and Saliva, Res. Comm. Chem. Path. Pharmacol. 10: 189-192 (1975). PMID: 1124317
55. Jusko WJ, Mosovich LL, Gerbracht LM, Mattar ME, and Yaffe SJ, Enhanced Elimination of Dicloxacillin in Patients with Cystic Fibrosis, Pediatrics 56: 1038-1044 (1975). PMID: 1196754
56. Koup JR, Jusko WJ, Elwood CM, and Kohli RK, Digoxin Pharmacokinetics: Role of Renal Failure in Dosage Regimen Design, Clin. Pharmacol. Ther. 18: 9-21 (1975). PMID: 1149366
57. Koup JR, Jusko WJ, Goldfarb AL, pH-Dependent Secretion of Procainamide into Saliva, J. Pharm. Sci. 64; 2008-2010 (1975). PMID: 1514
58. Koup JR, Greenblatt DJ, Jusko WJ, Smith TW, and Koch-Weser J, Pharmacokinetics of Digoxin in Normal Subjects After Intravenous Bolus and Infusion Doses, J. Pharmacokin. Biopharm. 3: 181-192 (1975). PMID: 1159622
59. Lewis GP and Jusko WJ, Pharmacokinetics of Ampicillin in Cirrhosis, Clin. Pharmacol. Ther. l8: 475-484 (1975). PMID: 1164828
60. Jusko WJ, Drug Dosage Adjustments in Diseased Patients, Rational Drug Therapy 10: 1-8 (1976). PMID: 951505
61. Gorodischer R, Jusko WJ, and Yaffe SJ, Renal Clearance of Digoxin in Young Infants, Res. Comm. Chem. Path. Pharmacol. 16: 363-374 (1977). PMID: 847290
62. Gorodischer R, Jusko WJ, and Yaffe SJ, Tissue and Erythrocyte Distribution of Digoxin in Infants, Clin. Pharmacol. Ther. 19: 256-263 (1976). PMID: 1261163
63. Koup JR, DeLattre M, Jusko WJ, and Vance JW, Caution in the Use of Variable Heparin Strengths, Drug Intell. Clin. Pharm. 9: 387-388 (1975).
64. Jusko WJ, Bioavailability Monograph on "Ampicillin", J. Am. Pharmaceut. Assn., NS 15: 591-594 (1975). PMID: 1184921
65. Jusko WJ and Poliszczuk A, Analysis of Theophylline in Biological Fluids by HPLC, Dupont Liquid Chromatography Applications Report, DuPont Instruments, Wilmington, Del. (1975).
66. Yurchak AM and Jusko WJ, Theophylline Secretion into Breast Milk, Pediatrics 57: 518-520 (1976). PMID: 1264548
67. Jusko WJ, Baliah T, Kim KH, Gerbracht LM, and Yaffe SJ, Pharmacokinetics of Gentamicin During Peritoneal Dialysis in Children, Kidney International 9: 430-438 (1976). PMID: 940277
68. Jusko WJ and Gretch M., Plasma and Tissue Protein Binding of Drugs in Pharmacokinetics, Drug Met. Rev. 5: 43-140 (1976). PMID: 829788 & PMID: 780085
69. Hunt SN, Jusko WJ, Yurchak AM, Effect of Smoking on Theophylline Disposition, Clin. Pharmacol. Ther. 19: 546-551 (1976). PMID: 1277710
70. Thiessen JJ, Bernardo PD, Seitz J, and Jusko WJ, Prednisolone: Bioavailability Monograph, J. Am. Pharm. Assn. NS 16: 143-146 (1976).
71. Jusko WJ, Bioavailability and Disposition Kinetics of Phenytoin in Man, In: "Quantitative Analytic Studies in Epilepsy", Kellaway P and Peterson I., editors, Raven Press, New York, 115-136 (1976).
72. Jusko WJ, Koup JR, and Alvan G, Nonlinear Assessment of Phenytoin Bioavailability, J. Pharmacokin. Biopharm. 4: 327-336 (1976). PMID: 978395
73. Jusko WJ, Pharmacokinetics in Disease States Changing Protein Binding, Chapter 7, in: "The Effects of Disease States on Drug Pharmacokinetics," L Benet, editor, Acad. Pharmaceut. Sci., Washington, D.C., 99-123 (1976).
74. Parsons RL, Jusko WJ, and Young JM, Pharmacokinetics of Antibiotic Absorption in Coeliac Disease, J. Antimicrob. Chemother. 2: 214-215 (I976). PMID: 956085
75. Koup JR, Schentag JJ, Vance JW, Kuritzky PM, Pyszczynski DR, and Jusko WJ, System for Clinical Pharmacokinetic Monitoring of Theophylline Therapy, Am. J. Hosp. Pharm. 33: 949-956 (1976). PMID: 790952
76. Jusko WJ and Poliszczuk A, High Pressure Liquid Chromatographic and Spectrophotometric Assays for Theophylline in Biological Fluids, Am. J. Hosp. Pharm. 33: 1193-1196 (1976). PMID: 998637
77. Giacoia G, Jusko WJ, Menke J, and Koup JR, Theophylline Pharmacokinetics in Premature Infants with Apnea, J. Ped. 89: 829-32 (1976). PMID: 789845
78. Yaffe SJ, Gerbracht LM, Mosovich LL, Mattar ME, and Jusko WJ, Methicillin Pharmacokinetics in Cystic Fibrosis, J. Inf. Dis. 135: 828-831 (1977). PMID: 404369
79. Jusko WJ, Koup JR, Vance JW, Kuritzky PM, and Schentag JJ, Intravenous Theophylline Therapy: Nomogram Guidelines, Ann. Int. Med., 86: 400-404 (1977). PMID: 848801
80. Schentag JJ and Jusko WJ, Gentamicin Persistence in the Body, The Lancet i: 486 (1977). PMID: 65590
81. Rose JQ, Choi HK, Schentag JJ, Kinkel WR, and Jusko WJ, Intoxication Caused by Interaction of Chloramphenicol and Phenytoin, JAMA 237: 2630-2631 (1977). PMID: 576989
82. Resman BH, Blumenthal HP, and Jusko WJ, Breast-Milk Distribution of Theobromine from Chocolate, J. Ped. 91: 477-480 (1977). PMID: 894424
83. Schentag JJ, Jusko WJ, Plaut ME, Cumbo TJ, Vance JW, and Abrutyn E, Tissue Persistence of Gentamicin in Man, JAMA 238: 327-329 (1977).

PMID: 406431
84. Schentag JJ, and Jusko WJ, Renal Clearance and Tissue Accumulation of Gentamicin in Man, Clin. Pharmacol. Ther. 22: 364-370 (1977). PMID: 330081
85. Schentag JJ, Jusko WJ, Vance JW, Cumbo TJ, Abrutyn E, DeLattre M, and Gerbracht LM, Gentamicin Disposition and Tissue Accumulation on Multiple Dosing, J. Pharmacokin. Biopharm. 5: 559-577 (1977). PMID: 599407
86. Lima JJ, Kuritzky PM, Schentag JJ, and Jusko WJ, Fetal Uptake and Neonatal Disposition of Procainamide and NAPA: A Case Report, Pediatrics 61: 491-493 (1978). PMID: 643424
87. Lima JJ and Jusko WJ, Determination of Procainamide Acetylator Status, Clin. Pharmacol. Ther. 23: 25-29 (1978). PMID: 618707
88. Jusko WJ, Role of Tobacco Smoking in Pharmacokinetics, J. Pharmacokin. Biopharm. 6: 7-39 (1978). PMID: 349132
89. Lima JJ and Jusko WJ, Micromethod for Procainamide and Its Acetylated Metabolite by HPLC, In: GL Hawk, editor; Biological/Biochemical Application of Liquid Chromatography, Marcel Dekker,, New York, 10: 573-583 (1979).
90. Gal P, Jusko WJ, Yurchak AM, and Franklin BA, Theophylline Disposition in Obesity, Clin Pharmacol.Ther 23: 438-444 (1978). PMID: 630791
91. Mangione A, Imhoff TE, Lee RV, Shum LY, and Jusko WJ, Pharmacokinetics of Theophylline in Hepatic Disease, Chest 73: 616-622 (1978). PMID: 648214
92. Jusko WJ, Schentag JJ, Clark JH, Gardner M, and Yurchak AM, Enhanced Biotransformation of Theophylline in Marihuana and Tobacco Smokers, Clin. Pharmacol. Ther. 24: 406-410 (1978). PMID: 688731
93. Schentag JJ, Lasezkay G, Plaut ME, Jusko WJ, and Cumbo TJ, Tissue Accumulation and Prolonged Washout of Gentamicin and Tobramycin in Humans, Current Chemotherapy 2: 957-959 (1978).
94. Colburn WA, Schentag JJ, Jusko WJ, and Gibaldi, M., A Model for the Prospective Identification of the Pre-Nephrotoxic State During Gentamicin Therapy, J. Pharmacokin. Biopharm. 6: 179-186 (1978). PMID: 671224
95. MacKichan JJ, Pyszczynski DR, and Jusko WJ, Analysis and Disposition of Low Dose Oral Propranolol, Res. Commun. Chem. Pathol. Pharmacol. 20: 531-538 (1978). PMID: 674830
96. Owerbach J, Johnson NF, Bates TR, Pieniaszek HJ, and Jusko WJ, High Performance Liquid Chromatograph Assay of Sulfapyridine and Acetylsulfapyridine in Biological Fluids, J. Pharm. Sci. 67: 1250-53 (1978). PMID: 690830
97. Schentag JJ, Lasezkay G, Cumbo TJ, Plaut ME, and Jusko WJ, Accumulation Pharmacokinetics of Tobramycin, Antimicrob. Agents Chemother. 13: 649-656 (1978). PMID: 666293
98. Rose JQ. Barron SA, and Jusko WJ, Phenytoin Disposition in Smokers and Nonsmokers, Int. J. Clin. Pharmacol. Biopharm. 16: 547-550 (1978). PMID: 730422
99. Jusko WJ, Therapeutic Implications of Digoxin Kinetics in Impaired Renal Function, Proc. Int. Symposium on Cardiac Glycosides, G Bodem and HJ Dengler, Eds., Bonn-1977, pp. 265-272 (1978).
100. Rose JQ and Jusko WJ, Corticosteroid Analysis in Biological Fluids by High Performance Liquid Chromatography, J. Chromatogr. 162: 273-280 (1979). PMID: 528595
101. Schentag JJ, Lasezkay G, Plaut ME, Jusko WJ, and Cumbo TJ, Comparative Tissue Accumulation of Gentamicin and Tobramycin in Patients, J. Antimicrob. Chemother. 4 (Suppl. A): 23-30 (1978). PMID: 659346
102. Lima JJ, Conti DR, Goldfarb AL, Golden LH, and Jusko WJ, Pharmacokinetic Approach to Intravenous Procainamide Therapy, Europ. J. Clin. Pharmacol. 13: 303-308 (1978). PMID: 668789
103. Schentag JJ, Cumbo TJ, Jusko WJ, Plaut ME, Gentamicin Tissue Accumulation and Nephrotoxic Reactions, JAMA 240: 2067-9 (1978). PMID: 702701
104. Lima JJ, Conti DR, Goldfarb AL, Tilstone WJ, Golden LH, and Jusko WJ, Clinical Pharmacokinetics of Procainamide Infusions in Relation to Acetylator Phenotype, J. Pharmacokin. Biopharm. 7: 69-85 (1979). PMID: 458558
105. Schentag JJ, Jusko WJ, Vance J, Cumbo TJ, Abrutyn E., and Plaut ME, Aminoglycoside Nephrotoxicity in Relation to Tissue Accumulation, In: Nephrotoxicity, J-P Fillastre, Ed., Masson Publ. Inc., New York (1978), pp. 63-82.
106. Schentag JJ, Sutfin TA, Plaut ME, and Jusko WJ, Early Detection of Aminoglycoside Nephrotoxicity with Urinary Beta Microglobulin, J. Med. 9: 201-210 (1978). PMID: 84037
107. Lima JJ, Goldfarb AL, Conti DR, Golden LH, Bascomb BL, Benedetti GM, and Jusko WJ, Safety and Efficacy of Procainamide Infusions, Am. J. Cardiol. 43: 98-105 (1979). PMID: 758776
108. Sutfin TA and Jusko WJ, High Performance Liquid Chromatographic Assay for Imipramine, Desipramine, and Their 2-Hydroxylated Metabolites, J. Pharm. Sci. 68: 703-705 (1979). PMID: 458567
109. MacKichan JJ, Pyszczynski DR, and Jusko WJ, Dose-Dependent Disposition of Oral Propranolol in Normal Subjects, Biopharm. Drug Disp. 1: 159-166 (1980). PMID: 7448344
110. Jusko WJ, Influence of Cigarette Smoking on Drug Metabolism in Man, Drug Metab. Rev. 9: 221-236 (1979). PMID: 385272
111. MacKichan JJ and Jusko WJ, Stability of Hydrocortisone in Human Feces, J. Pharm. Sci. 68: 623-625 (1979). PMID: 430502
112. Hilligoss DM, Jusko WJ, Hart BA, Koup JR, and Giacoia G, Factors Affecting Theophylline Pharmacokinetics in Premature Infants with Apnea, Dev. Pharmacol. Ther. 1: 6-15 (1980). PMID: 7438966
113. Plaut ME, Schentag JJ, and Jusko WJ, Aminoglycoside Nephrotoxicity: Comparative Assessment in Critically Patients, J. Med. 10: 257-266 (1979). PMID: 294466
114. Potter WZ, Calil HM, Zavadil AP, Jusko WJ, Sutfin T, Rapoport JL, and Goodwin FK. Steady-State Concentrations of Hydroxylated Metabolites of Tricyclic Antidepressants in Patients: Relationship to Clinical Effect, Psychopharmacol. Bull. 16: 32-34 (1980).
115. Lima JJ, Giller J, MacKichan JJ, and Jusko WJ, Bioavailability of Hydrocortisone Retention Enemas in Normal Subjects, Am. J. Gastroenterol. 73: 232-237 (1980). PMID: 7405924
116. Jusko WJ, Concepts for Population Pharmacokinetics of Theophylline, In: 25 Jahre Pharmakokinetik (Symposium), E Gladke and G Hermin, Eds., Gustov Fisher Verlag, Stuttgart, pp. 181-189 (1980).
117. Jusko WJ, Gardner M, Mangione A, Schentag JJ, Koup JR, and Vance JW, Factors Affecting Theophylline Clearances: Age, Tobacco, Marihuana, Cirrhosis, Congestive Heart Failure, Obesity, Oral Contraceptives, Benzodiazepines, Barbiturates, and Ethanol, J. Pharm. Sci. 68: 1358-1366 (1979). PMID: 41932
118. Schentag JJ, Gengo FM, Plaut ME, Danner D, Mangione A, and Jusko WJ., Urinary Casts as an Indicator of Renal Tubular Damage in Patients, Antimicrob. Ag. Chemother. 16: 468-474 (1979). PMID: 518076
119. MacKichan JJ, Jusko WJ, Duffner PK, and Cohen ME, Liquid Chromatographic Assay of Diazepam and Its Major Metabolites in Plasma, Clin.

Chem. 25: 856-859 (1979). PMID: 448518
120. Rose JQ, Yurchak AM, Jusko WJ, and Powell D, Bioavailability and Disposition of Prednisone and Prednisolone from Prednisone Tablets, Biopharm. Drug Disp. 1: 247-258 (1980).
121. Rose JQ. Yurchak AM, Meikle AQ, and Jusko WJ, Effect of Smoking on Prednisone, Prednisolone, and Dexamethasone Pharmacokinetics, J. Pharmacokin. Biopharm. 9: 1-14 (1981). PMID: 7229914
122. DeVane CL, Wolin RE, and Jusko WJ, Pharmacokinetic Basis for Predicting Steady-State Serum Drug Concentrations of Imipramine from Single Dose Data, Res. Commun. Psychopharm, 3: 353-357 (1979). PMID: 548214
123. Lima JJ and Jusko WJ, The Bioavailability of Hydrocortisone Retention Enemas in Relation to Absorption Kinetics, Clin. Pharmacol. Ther. 28: 262-269 (1980). PMID: 7398193
124. Janssen FW, JuskoWJ, Chiang ST, Kirkman SK, Southgate PJ, Coleman AJ, and Ruelius HW, Metabolism and Pharmacokinetics of Oxaprozin in Normal Subjects, Clin. Pharmacol. Ther. 27: 352-362 (1980). PMID: 7357792
125. Rocci ML, Johnson NF, and Jusko WJ, Serum Protein Binding of Prednisolone in Four Species, J. Pharm. Sci. 69: 977-978 (1980). PMID: 7400951
126. Jusko WJ, Therapeutic Drug Monitoring: Pharmacokinetic Aspects, In: Breimer, DD, Editor, Towards Better Safety of Drugs and Pharmaceutical Products, pp. 153-165, Elvesier/North-Holland Biomedical Press (1980).
127. Assael BM, Cavanna G, Jusko WJ, Marini A, Parini R, Sereni F, and Vigano A., Multiexponential Elimination of Gentamicin. A Kinetic Study During Development, Dev. Pharmacol. Ther. 1: 171-181 (1980). PMID: 6927546
128. Jusko WJ and Rose JQ, Monitoring Prednisone and Prednisolone, Ther. Drug Monit. 2: 169-176 (1980). PMID: 6762710
129. Rose JQ, Nickelsen, JA, Middleton E, Yurchak AM, Park B, and Jusko WJ, Prednisolone Disposition in Steroid Dependent Asthmatics, J. Allerg. Clin. Immunol. 66: 366-373 (1980). PMID: 7440853
130. Tognoni G., Latini R., and Jusko WJ, Editors, Frontiers in Therapeutic Drug Monitoring, Raven Press, NY (1980).
131. Szefler SJ, Rose JQ, Ellis EF, Spector SL, Green AW, and Jusko WJ, The Effect of Troleandomycin on Methylprednisolone Disposition, J. Allerg. Clin. Immunol. 66: 447-451 (1980). PMID: 6968763
132. Jusko WJ, Guidelines for Collection and Pharmacokinetic Analysis of Drug Disposition Data, In: Evans, WE., Schentag J.J, and Jusko WJ, Eds., Applied Pharmacokinetics, Appl. Ther. Inc., San Francisco, pp. 639-680 (1980).
133. Evans WE, Schentag JJ, and Jusko WJ, Eds, Applied Pharmacokinetics, Applied Therapeutics Inc., San Francisco (1980).
134. Rocci ML, Szefler SJ, Acara M, and Jusko WJ, Prednisolone Metabolism and Excretion in the Isolated Perfused Rat Kidney, Drug Met. Disp. 9: 177-182 (1981). PMID: 6113924
135. DeVane CL, Wolin RE, Rovere RA, Panahon NC, Sutfin TA, and Jusko WJ, Excessive Plasma Concentrations of Tricyclic Antidepressants Resulting from Usual Doses: A Report of Six Cases, J. Clin. Psych. 42: 143-147 (1981). PMID: 7204359
136. Rose JQ, Yurchak AM, and Jusko WJ, Dose-Dependent Pharmacokinetics of Prednisone and Prednisolone in Man, J. Pharmacokin. Biopharm. 9: 389-417 (1981). PMID: 7310640
137. Rose JQ. Nickelsen JA, Ellis EF, Middleton E, Park B, and Jusko WJ, Prednisolone Disposition in Steroid Dependent Asthmatic Children, J. Allerg. Clin. Immunol. 67: 188-193 (1981). PMID: 7462536
138. DeVane CL, Savett M, and Jusko WJ, Desipramine and 2-HydroxyDesipramine Pharmacokinetics in Normal Volunteers, Eur. J. Clin. Pharmacol. 19: 61-64 (1981). PMID: 7461025
139. DeVane CL and Jusko WJ, Pharmacokinetics of High Clearance Drugs and Their Metabolites, In: Usdin,E., Dahl SG., Gram L., Linghaerde 0., Eds., Clinical Pharmacology in Psychiatry, MacMillan &Co., London, pp. 253-261 (1981).
140. DeVane CL and Jusko WJ, Plasma Concentration Monitoring of Hydroxylated Metabolites of Imipramine and Desipramine, Drug Intell. Clin. Pharm. 15: 263-266 (1981). PMID: 7274042
141. Janicke DM, Mangione A, Schultz R, and Jusko WJ, Mezlocillin Disposition in Chronic Hemodialysis Patients, Antimicrob. Agents Chemother. 20: 590-594 (1981). PMID: 6459760
142. Jusko WJ, Smoking and Drug Response, Pharmacy Int. 2: 10-13 (1981).
143. Rocci ML and Jusko WJ, Analysis of Prednisone, Prednisolone, and Their 20-Beta-Hydroxylated Metabolites by High Performance Liquid Chromatography, J. Chrom. Biomed. Appl. 224: 221-227 (1981).
144. Rocci ML and Jusko WJ, Blood Collection Technique: No Effect on In Vitro Protein Binding of Prednisolone, J. Pharm. Sci. 70: 1160-1161 (1981). PMID: 7299653
145. Rocci ML and Jusko WJ, Dose-Dependent Protein Binding and Disposition of Prednisolone in Rabbits, J. Pharm. Sci. 70: 1201-04 (1981). PMID: 7299663
146. Jusko WJ and Chiang ST, Distribution Volume Related to Body Weight and Protein Binding, J. Pharm. Sci. 71: 469-470 (1982). PMID: 7086663
147. DeVane CL and Jusko WJ, Dosage Regimen Design, Pharmacol. Ther. 17: 143-163 (1982). PMID: 6757976
148. Gardner MJ, Jusko WJ, Effect of Age and Sex on Theophylline Clearances in Young Subjects, Ped Pharmacol. 2: 157-69 (1982). PMID: 12760407
149. Mangione A, Janicke DM, Boudinot FD, Schultz RM, and Jusko WJ, Dose-Dependent Pharmacokinetics of Mezlocillin in Subjects with Normal and Impaired Renal Function, J. Antimicrob. Chemother. 9: Suppl. A, 81-85 (1982). PMID: 6210686
150. Potter WZ, Calil HM, Sutfin TA, Zavadil AP, Jusko WJ, Rapoport J and Goodwin FK, Active Metabolites of Imipramine and Desipramine in Man, Clin. Pharmacol. Ther. 31: 393-401 (1982). PMID: 7060321
151. Rocci ML, D'Ambrosio R, Johnson NF, and Jusko WJ, Prednisolone Binding to Albumin and Transcortin in the Presence of Cortisol, Biochem. Pharmacol. 31: 289-292 (1982). PMID: 7073761
152. Mangione A, Boudinot FD, Schultz RM, and Jusko WJ, Dose-Dependent Pharmacokinetics of Mezlocillin in Relation to Renal Impairment, Antimicrob. Ag. Chemother. 21: 428-435 (1982). PMID: 6213190
153. Meacham RH, Chiang ST, Kick CJ, Sisenwine SF. Jusko WJ, and Ruelius H, Pharmacokinetic Disposition of Guanabenz in the Rhesus Monkey, Drug Metab. Disp. 9; 509-514 (1982). PMID: 6120807
154. Pautler DB and Jusko WJ, Determination of Metoprolol and Alpha-Hydroxymetoprolol in Plasma by High Performance Liquid Chromatography, J. Chrom. Biomed. Appl. 228: 215-222 (1982). PMID: 7076745
155. Jusko WJ and Eaton ML, Factors Affecting Theophylline Disposition, In: Therapy Update, MacLeod SM.and Isles A eds., Astra Pharmaceuticals Canada Ltd., Mississauga, Ontario (1982) pp. 19-29.
156. Tornatore KM., Kanarkowski R, McCarthy TL, Gardner MJ, Yurchak AM, and Jusko WJ, Effect of Chronic Oral Contraceptive Steroids on

Theophylline Disposition, Eur. J. Clin. Pharmacol., 23: 129-134 (1982). PMID: 7140802
157. Szefler SJ, Ellis EF, Brenner M, Rose JQ, Spector SL, Yurchak AM, Andrew F, and Jusko WJ, Steroid-Specific and Anticonvulsant Interaction Aspects of Troleandomycin-Steroid Therapy, J. Allerg. Clin. Immunol., 69: 455-460 (1982). PMID: 6978898
158. Szefler SJ, Spector SL, Jusko WJ, Brenner M, Fleisher KA, and Ellis EF, Dose and Time-Dependent Effect of Troleandomycin on Methylprednisolone Elimination, Clin. Pharmacol. Ther. 32: 166-171 (1982). PMID: 6980076
159. Christoff PB, Conti DR, Naylor C and Jusko WJ, Procainamide Disposition in Obesity, Drug Intell. Clin. Pharm., 17: 516-522 (1983). PMID: 6191939
160. DeVane CL and Jusko WJ, Drug and Metabolite Concentrations Combined in Prediction of Steady-State Concentrations from Test Doses, Biopharm. Drug Disp., 4: 19-29 (1983). PMID: 6839000
161. Jusko WJ, Smoking Effects in Pharmacokinetics, In: Benet LZ, Gambertoglio JG, Massoud M, Eds., The Pharmacokinetic Basis of Drug Treatment, Raven Press, 311-320 (1982).
162. Rocci ML, Assael BM, Appiani AC, Edefonti A, and Jusko WJ, Effect of Nephrotic Syndrome on Absorption and Disposition of Prednisolone in Children, Int. J. Ped. Nephrol., 3: 159-166 (1982). PMID: 7141787
163. Assael BM. Banfi G, Appiani AC, Edefonti A, and Jusko WJ, Disposition of Pulse-Dose Methylprednisolone in Adult and Pediatric Patients with Nephrotic Syndrome, Eur. J. Clin. Pharmacol., 23: 429-433 (1982). PMID: 7151847
164. Milsap RL, George DE, Szefler SJ, Murray KA, Lebenthal E, and Jusko WJ, The Effects of Inflammatory Bowel Disease on Absorption and Disposition of Prednisolone, Dig. Dis. Sci., 28: 161-168 (1983). PMID: 6825536
165. Clarke DF, George D, Milsap RL, Pogonowska-Wala E, Owerbach J, Lebenthal E, and Jusko WJ, Sulfasalazine Metabolite Pharmacokinetics in Pediatric Patients with Inflammatory Bowel Disease: Effects of Disease Activity, Acetylator Phenotype and Age. Ped. Pharmacol. 2: 323-333 (1982). PMID: 6152489
166. Milsap RL and Jusko WJ, Binding of Prednisolone to α_1-Acid Glycoprotein, J. Steroid Biochem., 18: 191-194 (1983). PMID: 6843123
167. Boekenoogen SJ, Szefler SJ, and Jusko WJ, Prednisolone Disposition and Protein Binding in Oral Contraceptive Users, J. Clin. Endocrin. Met. 56: 702-709 (1983). PMID: 6833459
168. Gardner MJ, Tornatore KM, Jusko WJ, and Kanarkowski R, Effects of Tobacco Smoking and Oral Contraceptive Use on Theophylline Disposition, Brit. J. Clin. Pharmacol. 16: 271-280 (1983). PMID: 6626419
169. Rocci ML and Jusko WJ, LAGRAN Program for Area and Moments in Pharmacokinetic Analysis, Comput. Progr. Biomed., 16: 203-216 (1983). PMID: 6688572
170. Fava GA, Molnar G, Carson SW, Perini GI, Jusko WJ, The Metyrapone Test in Depression, Neuroendocr Lett 5: 259-63 (1983).
171. Gengo FM, Schentag JJ, and Jusko WJ, Pharmacokinetics of Capacity-Limited Tissue Distribution of Methicillin in Rabbits, J. Pharm. Sci., 73: 867-73 (1984). PMID: 6470946
172. Cuddy Stotter ML, Jusko WJ, Mangione A, Yurchak AM, Gardner MJ, and Paigen B, Theophylline Disposition in Residents Living Near a Chemical Waste Site, Biopharm. Drug Disp. 5: 345-355 (1984). PMID: 6525442
173. Khalafallah N and Jusko WJ, Tissue Distribution of Prednisolone in the Rabbit, J. Pharmacol. Exp. Ther. 229: 719-725 (1984). PMID: 6726655
174. Khalafallah N and Jusko WJ, Determination and Prediction of Tissue Binding of Prednisolone in the Rabbit, J. Pharm. Sci., 73: 362-366 (1984). PMID: 6716244
175. Sutfin TA, DeVane CL, and Jusko WJ, The Analysis and Disposition of Imipramine and Its Active Metabolites in Man, Psychopharmacol., 82: 310-317 (1984). PMID: 6427820
176. Boudinot FD and Jusko WJ, Fluid Shifts and Other Factors Affecting Plasma Protein Binding of Prednisolone by Equilibrium Dialysis, J. Pharm. Sci., 73: 774-780 (1984). PMID: 6204037
177. Gardner MJ and Jusko WJ, Endogenous Factors Affecting Theophylline Clearance, ln: JHG Jonkman, JW Jenne, and FER Simons, Eds., Sustained Release Theophylline, Excerpta Medica, Elsev. Sci. Publ., Amsterdam, pp. 52-66 (1984).
178. Green AW, Ebling WF, Gardner MJ, and Jusko WJ, Case Study of Cimetidine - Methylprednisolone - Theophylline Interaction, Am. J. Med., 77: 1115-18 (1984). PMID: 6507464
179. Ebling WF, Szefler SJ, and Jusko WJ, Analysis of Cortisol, Methylprednisolone, and Methylprednisolone Hemisuccinate: Absence on Effects of Troleandomycin on Ester Hydrolysis, J. Chrom., Biomed. Appl., 305: 271-280 (1984). PMID: 6368578
180. Fava GA, Carson SW, Perini GI, Morphy M, Molnar G, and Jusko WJ, The Metyrapone Test in Affective Disorders and Schizophrenia, J. Affect. Disord., 6: 241-247 (1984). PMID: 6235255
181. Fava GA, Morphy MA, Carson SW, Perini GI, Molnar G, and Jusko WJ, A Modified Metyrapone Test in Depressed Patients and Healthy Subjects, Neuroendocrinol. Lett. 6: 81-87 (l984).
182. Shum L and Jusko WJ, Theophylline Disposition in Obese Rats, J. Pharmacol. Exp. Ther., 228: 380-386 (1984). PMID: 6694116
183. Carson SW and Jusko WJ, Simultaneous Analysis of Cortexolone and Cortisol by High Performance Liquid Chromatography, J. Chromatogr., Biomed. Appl. 306: 345-350 (1984). PMID: 6715472
184. Gardner MJ, McCarthy TL, and Jusko WJ, Relationship of Serum Thiocyanate Concentrations to Smoking Characteristics, J. Toxicol. Environ. Health, 14: 393-406 (1984). PMID: 6502741
185. Sutfin TA, D'Ambrosio R, and Jusko WJ, Liquid Chromatographic Determination of Eight Tri- and Tetracyclic Antidepressants and Their Active Metabolites, Clin. Chem., 30: 471-474 (1984). PMID: 6697502
186. Boudinot FD and Jusko WJ. Plasma Protein Binding Interaction of Prednisone and Prednisolone, J. Steroid Biochem., 21: 337-9 (1984). PMID: 6492791
187. Lui N, Almon RR, and Jusko WJ, Comparison of Filtration and Equilibrium Dialysis Methods for ^{3}H-Imipramine Binding to Human Platelets, Anal. Biochem., 139: 42-57 (1984). PMID: 6331229
188. Janicke DM, Rubio TT, Wirth FH, Karotkin EH, and Jusko WJ, Developmental Pharmacokinetics of Mezlocillin in Newborn Infants, J. Ped. 104: 773-781 (1984). PMID: 6716226
189. Milsap RL, Plaisance KL, Jusko WJ, Pharmacokinetics of Prednisolone in Obese Men, Clin. Pharmacol. Ther. 36: 824-31 (1984). PMID: 6499362
190. Perini GI, Fava GA, Morphy MA, Carson SW, Molnar G, and Jusko WJ, The Metyrapone Test in Manic Patients and Healthy Subjects, Pharmacopsychiat. 17: 94-97 (1984). PMID: 6739539
191. Janicke DM, Cafarelli RF, Parker SW, Apicella MA, and Jusko WJ, Pharmacokinetics of Aztreonam in Patients with Gram-Negative Infection, Antimicrob. Ag. Chemother., 27: 16-20 (1985). PMID: 4039117

192. Perini GI, Fava GA, Carson SW, Morphy MA, Molnar G, and Jusko WJ, The Metyrapone Test in Affective Disorders and Schizophrenia II: Changes Upon Treatment, J. Affect. Disord., 7: 265-272 (1984). PMID: 6151957
193. Ebling WF, Szefler SJ, and Jusko WJ, Methylprednisolone Disposition in Rabbits: Analysis, Pro-drug Conversion, Reversible Metabolism, and Comparison with Man, Drug Met. Disp., 13: 296-304 (1985). PMID: 2861987
194. Boudinot FD, Homon CA, Jusko WJ, and Ruelius HW, Protein Binding of Oxazepam and its Glucuronide Conjugates to Human Albumin, Biochem. Pharmacol., 34: 2115-2121 (1985). PMID: 4004929
195. Morphy MA, Fava GA, Carson SW, Perini GI, Molnar G, and Jusko WJ, The Metyrapone Test in Schizophrenic Patients and Healthy Subjects, Neuropsychobiol., 14: 35-38 (1985). PMID: 4069347
196. Sutfin TA and Jusko WJ, Compendium of Active Drug Metabolites, In: Drug Metabolism and Disposition, MD Rawling and GR Wilkinson, Eds., MTP Press Ltd, Lancaster, UK, pp. 91-159, (1985).
197. Morse GD, Janicke DM, Cafarell RF, Piontek K, Apicella M., Jusko WJ, and Walshe J, Moxalactam Epimer Disposition in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis, Clin. Pharmacol. Ther., 38: 150-156 (1985). PMID: 4017417
198. Morse GD, Janicke DM, Cafarell RF, Apicella MA, Jusko WJ, Venuto RC, and Walshe JJ, IP Administration of Moxalactam During CAPD, Frontiers in Peritoneal Dialysis, Field, Rich, Assoc., NY, pp. 135-140 (1986).
199. Ebling WF, Milsap RL, Szefler SJ, and Jusko WJ, 6α-Methylprednisolone and 6α-Methylprednisone Plasma Protein Binding in Humans and Rabbits, J. Pharm. Sci., 75: 760-763 (1986). PMID: 3772747
200. Janicke DM, Morse GD, Apicella MA, Jusko WJ, and Walshe JJ, Pharmacokinetic Modeling of Bidirectional Transfer During Peritoneal Dialysis, Clin. Pharmacol. Ther., 40: 209-218 (1986). PMID: 3731683
201. Szefler SJ, Ebling WF, Georgitis J, and Jusko WJ, Methylprednisolone versus Prednisolone Pharmacokinetics in Relation to Dose in Adults, Eur. J. Clin. Pharmacol. 30: 323-329 (1986). PMID: 3732369
202. Jusko WJ, Guidelines for Collection and Analysis of Pharmacokinetic Data, In: Applied Pharmacokinetics, Sec. Ed., WE Evans, JJ Schentag, and WJ Jusko, Eds., Applied Therapeutics Inc., San Francisco, CA, pp. 9-54 (1986).
203. Evans WE, Schentag JJ, and Jusko WJ, Eds, Applied Pharmacokinetics, Sec. Ed., Applied Ther. Inc., SF, CA (1986).
204. Ebling W and Jusko WJ, The Determination of Essential Clearance, Volume, and Residence Time Parameters of Recirculating Metabolic Systems: The Reversible Metabolism of Methylprednisolone and Methylprednisone in Rabbits, J. Pharmacokin. Biopharm. 14: 557-599 (1986). PMID: 3820091
205. Gardner MJ and Jusko WJ, Effects of Oral Contraceptives and Tobacco Use on the Metabolic Pathways of Theophylline, Int. J. Pharmaceut., 33 55-64 (1987).
206. Glynn AM, Slaughter RL, Brass C, D'Ambrosio R, and Jusko WJ, Effects of Ketoconazole on Methylprednisolone Pharmacokinetics and Cortisol Secretion, Clin. Pharmacol. Ther. 39: 654-659 (1986). PMID: 3709030
207. Shum L and Jusko WJ, Pharmacokinetics of Tritiated Water in Normal and Dietary-Induced Obese Rats, J. Pharmacol. Methods, 16: 83-89 (1986). PMID: 3747548
208. Jusko WJ, The Role of the Pharmacist in Clinical Research, In: DD Breimer and P Speiser, eds, Topics in Pharmaceutical Sciences, Elsevier Sci. Publ., Amsterdam, pp. 417-430 (1985).
209. Shum L and Jusko WJ, Reversed-Phase High-Performance Liquid Chromatographic Determination of Verophylline in Rat Serum, J. Chromatogr. Biomed. Appl. 382: 207-213 (1986). PMID: 3782387
210. Jungbluth GL, Cooper DL, Doyle GD, Chudzik GM, and Jusko WJ, Pharmacokinetics of Ticarcillin and Clavulanic Acid (Timentin) in Relation to Renal Function, Antimicrob. Ag. Chemother., 30:896-900 (1986). PMID: 3492959
211. Boudinot FD and Jusko WJ, Dose-Dependent Pharmacokinetics of Prednisolone in Normal and Adrenalectomized Rats, J. Pharmacokin. Biopharm., 14: 453-467 (1986). PMID: 3806371
212. Boudinot FD, D'Ambrosio R, and Jusko WJ, Receptor-Mediated Pharmacodynamics of Prednisolone in the Rat, J. Pharmacokin. Biopharm., 14: 469-493 (1986). PMID: 2879901
213. Chow AT and Jusko WJ, Application of Moment Analysis to Nonlinear Drug Disposition Described by the Michaelis-Menten Equation, Pharmaceut. Res., 4: 59-61 (1987). PMID: 3508531
214. Shum L and Jusko WJ, Theophylline Tissue Partitioning and Volume of Distribution in Normal and Dietary-Induced Obese Rats, Biopharm. Drug Disp. 8: 353-364 (1987). PMID: 3620594
215. Ebling WF, Rich SA, Szefler SJ, and Jusko WJ, Troleandomycin Effects on Methylprednisolone and Methylprednisone Interconversion and Disposition in the Rabbit, Eur. J. Drug Met. Pharmacokin., 12: 49-57 (1987). PMID: 3497038
216. Gardner MJ, Schatz M, Cousins L, Zeigler R., Middleton E., and Jusko WJ, Longitudinal Effects of Pregnancy on the Pharmacokinetics of Theophylline, Europ. J. Clin. Pharmacol., 32: 289-295 (1987). PMID: 3595701
217. Kandrotas RJ, Slaughter RL, Brass C, and Jusko WJ, Ketoconazole Effects on Methylprednisolone Disposition and Their Joint Suppression of Endogenous Cortisol, Clin. Pharmacol. Ther., 42: 465-470 (1987). PMID: 3311551
218. Sutfin TA, Perini GI, Molnar G, and Jusko WJ, Multiple-Dose Pharmacokinetics of Imipramine and Its Major Active and Conjugated Metabolites in Depressed Patients, J. Clin. Psychopharm., 8: 48-53 (1988). PMID: 3350999
219. Haughey DB and Jusko WJ, Theophylline Disposition in Foundry Workers Exposed to Coke Oven Effluent, Biopharm. Drug Disp., 9: 405-409 (1988). PMID: 3207860
220. Kanarkowski R, Tornatore DM, D'Ambrosio R, Gardner MJ, and Jusko WJ, Pharmacokinetics of Single and Multiple Doses of Ethinylestradiol and Levonorgestrel in Relation to Smoking, Clin. Pharmacol. Ther., 43: 23-31 (1988). PMID: 3121231
221. Jungbluth GL, Wirth FH, Rubio TT, Janicke DM, and Jusko WJ, Developmental Pharmacokinetics of Mezlocillin in 4 Newborn Infants, Dev. Pharmacol. Ther. 11: 317-321 (1988). PMID: 3229277
222. Cheng H and Jusko WJ, Mean Residence Time Concepts for Pharmacokinetic Systems with Nonlinear Drug Elimination Described by the Michaelis-Menten Equation, Pharm. Res. 5: 156-164 (1988). PMID: 3244627
223. Kong A-N and Jusko, WJ, Definitions and Applications of Mean Transit and Residence Times in Reference to the Two-Compartment Mammillary Plasma Clearance Model, J. Pharm. Sci. 77: 157-165 (1988). PMID: 3361431
224. Matsumoto RM, Jusko WJ, and Corcoran GB, Cytochrome P450 and In Vitro Drug Metabolism in an Overfed Rat Model of Obesity, Drug Nutr. Int. 5: 237-247 (1988). PMID: 3149237
225. Green C, Kraus C, Lemonske R, Farrell P, and Jusko WJ, Rapid Methylprednisolone Clearance in a Patient with Cystic Fibrosis, Drug Intell. Clin. Pharm. 22: 876-878 (1988). PMID: 3234253

226. Janicke DM, Parker SW, Cafarell RF, Apicella MA, and Jusko WJ, Pharmacokinetics of Two Multiple-Dose Mezlocillin Regimens, Antimicrob. Agents Chemother. 32: 777-779 (1988). PMID: 3395106
227. Haughey DB and Jusko WJ, Analysis of Methylprednisolone, Methylprednisone and Corticosterone for Assessment of Methylprednisolone Disposition in the Rat, J. Chromatogr. Biomed. Appl. 430: 241-248 (1988). PMID: 3235500
228. Kong AN, Slaughter RL, and Jusko WJ, Simultaneous Analysis of Methylprednisolone Hemisuccinate, Cortisol, and Methylprednisolone by Normal-Phase High-Performance Liquid Chromatography in Human Plasma, J. Chromatogr. Biomed. Appl. 430: 308-314 (1988). PMID: 3065346
229. Cheng H and Jusko WJ, An Area Function Method for Calculating the Apparent Elimination Rate Constant of a Metabolite, J. Pharmacokin. Bioph. 17: 125-130 (1989). PMID: 2715930
230. Cheng H and Jusko WJ, The Area Function Method for Assessing the Drug Absorption Rate in Linear Systems with Zero-Order Input, Pharm. Res. 6: 133-139 (1989). PMID: 2762213
231. Cheng H and Jusko WJ, Application of Mean Residence Time Concepts to Pharmacokinetic Systems with Noninstantaneous Input and Nonlinear Elimination, Pharm. Res. 6: 4-12 (1989). PMID: 2717515
232. Cheng H and Jusko WJ, Mean Residence Time of Drugs Showing Simultaneous First-Order and Michaelis-Menten Kinetics, Pharmaceu. Res. 6: 258-261 (1989). PMID: 2726685
233. Jungbluth GL and Jusko WJ, Dose-Dependent Pharmacokinetics of Mezlocillin in Rats, Antimicrob. Ag. Chemother. 33: 839-843 (1989). PMID: 2764534
234. Jungbluth GL, Pasko MT, Beam TR, and Jusko WJ, Ceftriaxone Disposition in Open Heart Surgery Patients, Antimicrob. Ag. Chemother. 33: 850-856 (1989). PMID: 2764536
235. Jungbluth GL, Janicke DM, and Jusko WJ, Reversed-Phase High-Performance Liquid Chromatographic Assay for Determination of Mezlocillin in Human and Rat Biological Samples, J. Chromatogr. 494: 376-380 (1989). PMID: 2584336
236. Jungbluth GL and Jusko WJ, Ion-Paired Reversed-Phase High-Performance Liquid Chromatography Assay for Determination of Ceftriaxone in Human Plasma and Urine, J. Pharm.Sci. 78: 968-970 (1989). PMID: 2621584
237. Giacoia GP, Jungbluth GL, and Jusko WJ, Effect of Formula Feeding on Oral Absorption of Caffeine in Premature Infants, Dev. Pharmacol. Ther. 12: 205-210 (1989). PMID: 2766923
238. Shum L and Jusko WJ, Effects of Obesity and Ancillary Variables (Dialysis Time and Drug, Albumin, and Fatty Acid Concentrations) on Theophylline Serum Protein Binding, Biopharm. Drug Disp., 10: 549-562 (1989). PMID: 2611356
239. Kong A-N, Ludwig EA, Slaughter RL, DiStefano PM, DeMasi J, Middleton E, and Jusko WJ, Pharmacokinetics and Pharmacodynamic Modeling of Direct Suppression Effects of Methylprednisolone on Serum Cortisol and Blood Histamine in Human Subjects. Clin. Pharmacol. Ther. 46: 616-628 (1989). PMID: 2689044
240. Jungbluth GL, Pasko MT, and Jusko WJ, Factors Affecting Ceftriaxone Plasma Protein Binding During Open Heart Surgery, J. Pharm. Sci. 78: 807-811 (1989). PMID: 2600784
241. Nichols AI, Boudinot FD, and Jusko WJ, Second Generation Model for Prednisolone Pharmacodynamics in the Rat, J. Pharmacokin. Biopharm., 17: 209-227 (1989). PMID: 2571711
242. Nichols AI, D'Ambrosio R, Pyszczynski NA, and Jusko WJ, Pharmacokinetics and Pharmacodynamics of Prednisolone in Obese Rats, J. Pharmacol. Exp. Ther. 250: 963-970 (1989). PMID: 2778721
243. Cheng H and Jusko WJ, Relationships Between Steady-State and Single-Dose Plasma Drug Concentrations for Pharmacokinetic Systems with Nonlinear Elimination, Biopharm. Drug Disp. 10: 513-528 (1989). PMID: 2804255
244. Ludwig EA, Slaughter RL, Savliwala M, Brass C, and Jusko WJ, Steroid-Specific Effects of Ketoconazole on Corticosteroid Disposition: Unaltered Prednisolone Elimination, DICP: The Annals of Pharmacotherapy, 23: 858-861 (1989). PMID: 2596127
245. Jusko WJ, Pharmacokinetics of Capacity-Limited Pharmacokinetic Systems, J. Clin. Pharmacol, 29: 488-493 (1989). PMID: 2666450
246. Tornatore KM, Morse GD, Jusko WJ, and Walshe JJ, Methylprednisolone Disposition in Renal Transplant Recipients Receiving Triple Drug Suppression, Transplantation, 48: 962-965 (1989). PMID: 2595785
247. Cheng H and Jusko WJ, Effects of Variation in Drug Elimination on Five Methods for Assessing Zero-Order Drug Absorption Rates, Pharmaceut. Res. 7: 76-79 (1990). PMID: 2300540
248. Cheng H and Jusko WJ, Mean Residence Times of Multi-Compartmental Drugs Undergoing Reversible Metabolism, Pharmaceut. Res., 7: 103-107 (1990). PMID: 2300529
249. Kong A-N, Jungbluth GL, Pasko MT, Beam TR, and Jusko WJ, Pharmacokinetics of Methylprednisolone Sodium Succinate and Methylprednisolone in Patients Undergoing Cardiopulmonary Bypass. Pharmacother., 10: 29-34 (1990). PMID: 2179900
250. Jusko WJ, Corticosteroid Pharmacodynamics: Models for a Broad Array of Receptor-Mediated Pharmacologic Effects, J. Clin. Pharmacol., 30: 303-310 (1990). PMID: 1971281
251. Nichols AI and Jusko WJ, Receptor Mediated Prednisolone Pharmacodynamics in Rats: Model Verification Using a Dose-Sparing Regimen, J. Pharmacokin. Bioph., 18: 189-208 (1990). PMID: 1974305
252. Murata R, Haughey DB, and Jusko WJ, Effects of Thyroid Dysfunction on Prednisolone and Prednisone Interconversion and Disposition in the Rat, Drug. Met. Dispos., 18: 403-408 (1990). PMID: 1976060
253. Reiss WG, Slaughter RL, Ludwig EA, Middleton E, and Jusko WJ, Steroid Dose-Sparing: Pharmacodynamic Responses to Single Versus Divided Doses of Methylprednisolone in Man, J. Allergy Clin. Immunol., 85: 1058-1066 (1990). PMID: 2191992
254. Cheng H and Jusko WJ, Constant-Rate Intravenous Infusion Methods for Estimating Steady-State Volumes of Distribution and Mean Residence Times in the Body for Drugs Undergoing Reversible Metabolism, Pharm. Res., 7: 628-632 (1990). PMID: 2367330
255. Huang M-L and Jusko WJ, Nonlinear Pharmacokinetics and Interconversion of Prednisolone and Prednisone in Rats, J. Pharmacokin. Biopharm., 18: 401-421 (1990). PMID: 2266496
256. Cheng H and Jusko WJ, Mean Interconversion Times and Distribution Rate Parameters for Drugs Undergoing Reversible Metabolism, Pharm. Res., 7: 1003-1010 (1990). PMID: 2281028
257. Chow AT and Jusko WJ, Michaelis-Menten Metabolite Formation Kinetics: Equations Relating Area Under the Curve and Metabolite Recovery to the Administered Dose, J. Pharm. Sci., 79: 902-906 (1990). PMID: 2280360
258. Cheng H and Jusko WJ, Drug Redistribution and Mean Transit Time Concepts For Nonlinear Pharmacokinetic Systems, Biopharm. Drug Disp. 12: 73-79 (1991). PMID: 2039813
259. Cheng H and Jusko WJ, Noncompartmental Determination of the Mean Residence Time and Steady-State Volume of Distribution During

Multiple Dosing, J. Pharm. Sci., 80: 202-204 (1991). PMID: 2051333
260. Cheng H and Jusko WJ, Mean Residence Times and Distribution Volumes for Drugs Undergoing Linear Reversible Metabolism and Tissue Distribution and Linear or Nonlinear Elimination from the Central Compartments, Pharm. Res., 8:508-511 (1991). PMID: 1871048
261. Cheng H, Jusko WJ, and Gillespie WR, Relationships Between the Area Under the First Moment Curve After Single Bolus Injection and the Integral of Plasma Concentrations After Constant-Rate Intravenous Infusion, J. Pharm. Sci., 80: 507-510 (1991). PMID: 1880736
262. Kong A-N and Jusko WJ, Disposition of Methylprednisolone and Its Sodium Succinate Prodrug In Vivo and In Perfused Liver of Rats: Nonlinear and Sequential First-Pass Elimination, J. Pharm. Sci., 80: 409-415 (1991). PMID: 1880717
263. Veng-Pedersen P, Cheng H and Jusko WJ, Regarding Dose Independent Pharmacokinetic Parameters in Nonlinear Pharmacokinetics, J. Pharm. Sci., 80: 608-612 (1991). PMID: 1941554
264. Yamashita SK, Ludwig EA, Middleton E Jr. E and Jusko WJ, Lack of Pharmacokinetic and Pharmacodynamic Interactions Between Ketoconazole and Prednisolone, Clin. Pharmacol. Ther. 49: 558-570 (1991). PMID: 1827622
265. Cheng H and Jusko WJ, Mean Residence Time of Drugs in Pharmacokinetic Systems with Linear Distribution, Linear or Nonlinear Elimination and Noninstantaneous Input, J. Pharm. Sci. 80:1005-1006 (1991). PMID: 1783996
266. Dunn TE, Ludwig EA, Slaughter RL, Camara DS, and Jusko WJ, Pharmacokinetics and Pharmacodynamics of Methylprednisolone in Obesity, Clin. Pharmacol. Ther. 50: 536-549 (1991). PMID: 1827621
267. Cheng H and Jusko WJ, Pharmacokinetics of Linear Reversible Metabolic Systems, In: Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis, D.D'Argenio, Ed., Plenum Press, NY, p 13-20 (1991).
268. Jusko WJ, Pharmacokinetics/Dynamics of Corticosteroids, In: Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis, D. D'Argenio, Ed., Plenum Press, New York, pp. 61-68 (1991).
269. Garg V and Jusko WJ, Simultaneous Analysis of Prednisone, Prednisolone, and Their Major Hydroxylated Metabolites in Urine by High-Performance Liquid Chromatography, J. Chrom. Biomed. Appl., 567: 39-47 (1991). PMID: 1918259
270. Shum L and Jusko WJ, Verophylline Pharmacokinetics in Normal and Dietary-Induced Obese Rats: Role of Fat Mass and Protein Binding in Determining Volume of Distribution, Xenobiotica, 21: 1419-1430 (1991). PMID: 1763516
271. Haughey DB and Jusko WJ, Effect of Ketoconazole on Methylprednisolone Pharmacokinetics and Receptor/Gene-Mediated Pharmacodynamics, J. Pharmacol. Exper. Ther., 259: 826-832 (1991). PMID: 1941630
272. Jusko WJ, D'Ambrosio R, Monitoring FK506 Concentrations in Plasma and Whole Blood, Transplant Proc 23:2732-2735 (1991). PMID: 1721260
273. Wald JA, Salazar DE, Cheng H and Jusko WJ, Two-Compartment Basophil Cell Trafficking Model for Methylprednisolone Pharmacodynamics, J. Pharmacokin. Biopharm. 19: 521-536 (1991). PMID: 1783990
274. Jusko WJ, Kung L-P, and Schmelter RD, Immunopharmacokinetics of ^{111}In-CYT-103 in Ovarian Cancer Patients, In: Diagnosis of Colorectal and Ovarian Carcinoma: Application of Immunoscintigraphic Technology, Eds. R.T. Maguire and D. Van Nostrand, Marcel Dekker Inc., New York, 177-190 (1992). Also: Targeted Diagn. & Ther. 6: 177-190 (1990). PMID: 1576345
275. Garg V, Blum R, Wilner KD, and Jusko WJ, Effect of the Anti-Inflammatory Agent Tenidap on the Pharmacokinetics and Pharmacodynamics of Prednisolone, J. Clin. Pharmacol. 32: 222-230 (1992). PMID: 1564126
276. Haughey DB and Jusko WJ, Bioavailability and Nonlinear Disposition of Methylprednisolone/Methylprednisone in the Rat, J. Pharm. Sci. 80: 117-121 (1992). PMID: 1545348
277. Wald JA and Jusko WJ, Corticosteroid Pharmacodynamic Modeling: Osteocalcin Suppression by Prednisolone, Pharm. Res., 9: 1096-1098 (1992). PMID: 1409384
278. Jusko WJ and Ludwig EA, Corticosteroids, Chap. 27 in "Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring", Third Ed, WE Evans, JJ Schentag, WJ Jusko, Eds., Appl Ther. Inc., Vancouver, WA, pp. 27-1 to 34 (1992).
279. Evans WE, Schentag JJ, and Jusko WJ, Editors: Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, Third Edition, Applied Therapeutics Inc., Vancouver WA (1992) & Jusko WJ, Guidelines for Collection and Analysis of Pharmacokinetic Data, Chapter 2, pp: 1-43 (1992).
280. Fisher LE, Ludwig EA, Wald JA, Sloan RR, Middleton E, and Jusko WJ, Pharmacokinetics and Pharmacodynamics of Methylprednisolone When Administered at 8 AM versus 4 PM, Clin. Pharmacol. Ther., 51: 677-688 (1992). PMID: 1535301
281. Dove AM, Szefler SJ, Hill MR, Jusko WJ, Larsen GL and Accurso FJ, Altered Prednisolone Pharmacokinetics in Patients with Cystic Fibrosis, J. Pediatrics, 120: 789-794 (1992). PMID: 1578318
282. Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, and Chiang ST, Introduction of a Composite Parameter to the Pharmacokinetics of Venlafaxine and Its Active O-Desmethyl Metabolite, J. Clin. Pharmacol., 32: 716-724 (1992). PMID: 1487561
283. Haughey DB and Jusko WJ, Receptor-Mediated Methylprednisolone Pharmacodynamics in Rats: Steroid-Induced Receptor Down-Regulation, J. Pharmacokin. Biopharm. 20: 333-355 (1992). PMID: 1362219
284. Fisher LE, Ludwig EA, and Jusko WJ, Pharmacoimmunodynamics of Methylprednisolone: Trafficking of Helper T Lymphocytes, J. Pharmacokin. Biopharm. 20: 319-331 (1992). PMID: 1479558
285. Cheng H and Jusko WJ, Mean Residence Time of Oral Drugs Undergoing First-Pass and Linear Reversible Metabolism, Pharmaceut. Res., 10: 8-13 (1993). PMID: 8430064
286. Jusko WJ, Conceptualization of Drug Distribution to a Hypothetical Pharmacodynamic Effect Compartment, Clin. Pharmacol. Ther. 54: 112-113 (1993). PMID: 8330459
287. Ludwig EA, Kong A-N, Camara DS, and Jusko WJ, Pharmacokinetics of Methylprednisolone Hemisuccinate and Methylprednisolone in Chronic Liver Disease, J. Clin. Pharmacol. 33: 805-810 (1993). PMID: 8227476
288. Piekoszewski W and Jusko WJ, Plasma Protein Binding of Tacrolimus (FK506) in Man, J. Pharm. Sci., 82: 340-341 (1993). PMID: 7680714
289. Chow AT, Meek PD, and Jusko WJ, High-Pressure Liquid Chromatographic Assay of Theophylline in Dog Feces Following Oral Administration of Sustained-Release Products, J. Pharm. Sci., 82: 956-958 (1993). PMID: 8229696
290. Wald JA, Law RM, Ludwig EA, Sloan RR, Middleton E Jr., Jusko WJ, Evaluation of Dose-Related Pharmacokinetics and Pharmacodynamics of Prednisolone in Man, J. Pharmacokin. Biopharm., 20: 567-589 (1993). PMID: 1302763
291. Dubois DC, Almon RR, and Jusko WJ, Molar Quantification of Specific Messenger Ribonucleic Acid Expression in Northern Hybridization Using cRNA Standards, Analyt. Biochem. 210: 140-144 (1993). PMID: 7683846
292. Piekoszewski W, Chow FS, and Jusko WJ, Disposition of Tacrolimus (FK506) in Rabbits: Role of Red Cell Binding in Hepatic Clearance, Drug Met. Dispos., 21: 690-698 (1993). PMID: 7690698

293. Jusko WJ and Milsap RL, Pharmacokinetic Principles of Drug Distribution in Saliva, Ann NY Acad Sci, 694: 36-47 (1993). PMID: 8215084
294. Mishina EV, Straubinger RM, Pyszczynski NA, and Jusko WJ, Enhancement of Tissue Delivery and Receptor Occupancy of Methylprednisolone in Rats by a Liposomal Formulation, Pharm. Res., 10: 1402-1410 (1993). PMID: 8272400
295. Lew KH, Ludwig EA, Milad MA, Donovan K, Middleton E, Ferry JJ, and Jusko WJ, Gender-Based Effects on Methylprednisolone Pharmacokinetics and Pharmacodynamics, Clin. Pharmacol. Ther. 54: 402-414 (1993). PMID: 8222483
296. Pleyer U, Lutz S, Jusko WJ, Nguyen K, Narawane M, Rückert D, Mondino BJ, and Lee VHL, Ocular Absorption of Topically Applied FK506 from Liposomal and Oil Formulations in the Rabbit Eye, Invest. Ophth Vis. Sci., 34: 2737-42 (1993). PMID: 7688360
297. Milad MA and Jusko WJ, Pharmacodynamic Interpretation of Adrenocorticotropin Stimulation Tests, Annals Pharmacother. 27: 1195-1197 (1993). PMID: 8251686
298. Cheng H and Jusko WJ, Pharmacokinetics of Reversible Metabolic Systems, Biopharm. Drug Disp., 14: 721-766 (1993). PMID: 8298069
299. Dayneka N, Garg V, and Jusko WJ, Comparison of Four Basic Models of Indirect Pharmacodynamic Responses, J. Pharmacokin. Biopharm., 21: 457-478 (1993). PMID: 8133465
300. D'Ambrosio R, Girzaitis N, and Jusko WJ, Validation and Quality Assurance Program for Monitoring Tacrolimus (FK 506) Concentrations in Plasma and Whole Blood, Ther. Drug Monitor., 15: 414-426 (1993). PMID: 7504339
301. Lew KH and Jusko WJ, Pharmacodynamic Modeling of Cortisol Suppression from Fluocortolone, Europ. J. Clin. Pharmacol., 45: 581-583 (1993). PMID: 8157047
302. D'Ambrosio R, Stabler T, Kobayashi M, and Jusko WJ, Improved Procedures for Enzyme Immunoassay of Tacrolimus (FK 506) in Whole Blood, Clin. Chemistry, 40: 159-160 (1994). PMID: 7507007
303. Garg V and Jusko WJ, Pharmacodynamic Modeling of NSAIDs: Antipyretic Effect of Ibuprofen, Clin. Pharmacol. Ther., 55: 87-88 (1994). PMID: 8299322
304. Cheng H, Gong Y, and Jusko WJ, A Computer Program for Calculating Distribution Parameters for Drugs Behaving Nonlinearly Based on Disposition Decomposition Analysis, J. Pharm. Sci., 83: 110-112 (1994). PMID: 8138898
305. Ermer JC, Hicks DR, Wheeler SC, Kraml M, and Jusko WJ, Concomitant Etodolac Affects Neither the Unbound Clearance Nor the Pharmacologic Effect of Warfarin, Clin. Pharmacol. Ther., 55: 305-316 (1994). PMID: 8143396
306. Garg V and Jusko WJ, Bioavailability and Reversible Metabolism of Prednisone and Prednisolone in Man, Biopharm. Drug Dispos., 15: 163-172 (1994). PMID: 8011967
307. Garg V and Jusko WJ, Effect of Indomethacin on the Pharmacokinetics and Pharmacodynamics of Prednisolone in Rats, J. Pharm. Sci., 83: 747-750 (1994). PMID: 7915309
308. Mishina EV and Jusko WJ, Inhibition of Rat Splenocyte Proliferation with Methylprednisolone: In Vivo Effect of Liposomal Formulation, Pharm. Res., 11: 848-854 (1994). PMID: 7937524
309. Garg V, Hon YY, and Jusko WJ, Effects of Acute and Chronic Inflammation on the Pharmacokinetics of Prednisolone in Rats, Pharm. Res., 11: 541-544 (1994). PMID: 8058612
310. Troy SM, Hicks DR, Parker VD, Jusko WJ, Rofsky HE, and Porter RJ, Differences in Pharmacokinetics and Comparative Bioavailability Between Premarin and Estratab in Healthy Postmenopausal Women, Curr. Ther. Res., 55: 359-372 (1994).
311. Piekoszewski W, Chow FS, and Jusko WJ, Pharmacokinetic and Pharmacodynamic Effects of Coadministration of Methylprednisolone and Tacrolimus in Rabbits, J. Pharmacol. Exper. Ther., 269: 103-109 (1994). PMID: 7513355
312. D'Ambrosio R, Girzaitis N, and Jusko WJ, Multicenter Comparison of Tacrolimus (FK 506) Whole Blood Concentrations as Measured by the Abbott IM_X Analyzer and Enzyme Immunoassay with Methylene Chloride Extraction, Ther. Drug Monitor., 16: 287-292 (1994). PMID: 7521979
313. Milad MA, Ludwig EA, Lew KH, Kohli RK, and Jusko WJ, The Pharmacokinetics and Pharmacodynamics of Methylprednisolone in Chronic Renal Failure, Am. J. Ther., 1:49-57 (1994). PMID: 11835067
314. Mishina EV and Jusko WJ, Selected Tissue Distribution of Liposomal Methylprednisolone in Rats, Res. Commun. Chem. Path. Pharmacol., 84: 47-52 (1994). PMID: 8042008
315. Cheng H, Yu C, and Jusko WJ, An Algorithm and Computer Program for Calculating the Mean Transit Time and Distribution Rate Parameters of Generated Metabolites Undergoing Linear Tissue Distribution and Linear or Non-linear Central Elimination, Biopharm. Drug Disp. 15: 273-294 (1994). PMID: 8068866
316. Jusko WJ, Receptor-Mediated Pharmacodynamics of Corticosteroids, In: "Receptor-Mediated Biological Processes: Implications for Evaluating Carcinogenesis", HL Spitzer, TJ Slaga, WF Greenlee, M McClain, ed, Wiley-Liss, NY, pp. 261-270 (1994). PMID: 7972251
317. Jusko WJ and Ko HC, Physiologic Indirect Response Models Characterize Diverse Types of Pharmacodynamic Effects, Clin. Pharmacol. Ther., 56: 406-419 (1994). PMID: 7955802
318. Wald JA and Jusko WJ, Prednisolone Pharmacodynamics: Leukocyte Trafficking in the Rat, Life Sci., 55: PL371-378 (1994). PMID: 7968208
319. Jusko WJ, Pyszczynski NA, Bushway MS, D'Ambrosio R, and Mis SM, Fifteen Years of Operation of a High-Performance Liquid Chromatographic Assay for Prednisolone, Cortisol and Prednisone in Plasma, J. Chrom. Biomed. Appl., 658: 47-54 (1994). PMID: 7952131
320. Piekoszewski W, Chow FS, and Jusko WJ, Inhibition of Phytohaemagglutinin-Induced Lymphocyte Proliferation by Immunosuppressive Drugs: Use of Whole Blood Culture, Immunopharmacol. Immunotoxicol., 16: 389-401 (1994). PMID: 7798592
321. Binder J, Mishina EV, Jusko WJ, and Kupiec-Weglinski JW, Prolongation of Cardiac Allograft Survival in Rats by Liposome-Encapsulated Methylprednisolone, Transplantation, 58: 633-635 (1994). PMID: 8091492
322. The U.S. Multicenter FK506 Liver Study Group, Comparison of Tacrolimus (FK506) and Cyclosporine for Immunosuppression in Liver Transplantation, New Engl. J. Med., 331: 1110-1115 (1994). PMID: 7523946
323. Cheng H, Gillespie WR, and Jusko WJ, Mean Residence Time Concepts for Nonlinear Pharmacokinetic Systems, Biopharm. Drug Disp., 15: 627-641 (1994). PMID: 7888595
324. Mishina EV, Binder J, Kupiec-Weglinski JW, and Jusko WJ, Effect of Liposomal Methylprednisolone on Heart Allograft Survival and Immune Function in Rats, J. Pharmacol. Exp. Ther., 271: 868-874 (1994). PMID: 7965807
325. Milsap RL and Jusko WJ, Pharmacokinetics in the Infant, Environ. Health Persp., 102 [Suppl. 11]: 107-110 (1994). PMID: 7737034
326. Jusko WJ, Milad MA, Ludwig EA, Lew KH, and Kohli RK, Methylprednisolone Pharmacokinetics and Pharmacodynamics in Chronic Renal Failure, Clinical Nephol., 43: S16-S19 (1995). PMID: 7781199
327. Jusko WJ, Piekoszewski W, Klintmalm GB, Schaeffer M, Hebert MF, Piergies AA, Lee C, Schechter P, and Mekki QA, Pharmacokinetics of Tacrolimus (FK506) in Liver Transplant Patients, Clin. Pharmacol. Ther., 57: 281-290 (1995). PMID: 7535213

328. Xu Z-X, Lee M-J, Blum RA, and Jusko WJ, Pharmacodynamic Modeling of Prednisolone Effects on Natural Killer Cell Trafficking, Pharm. Res., 12: 459-463 (1995). PMID: 7617538
329. Fasanmade AA and Jusko WJ, An Improved Pharmacodynamic Model for Formation of Methemoglobin by Antimalarial Drugs, Drug Met. Disp., 23: 573-576 (1995). PMID: 7587933
330. Abouljoud MS, Levy MF, Klintmalm GB, and The US Multicenter Study Group, Hyperlipidemia After Liver Transplantation: Long-Term Results of the FK506/Cyclosporine: A US Multicenter Trial, Transplant. Proc., 27: 1121-1123 (1995). PMID: 7533360
331. Ko HC, Jusko WJ, Pharmacodynamic Modeling of Finasteride, a 5α-Reductase Inhibitor, Pharmacother., 15: 509-511 (1995). PMID: 7479205
332. Lee MJ, Straubinger RM, and Jusko WJ, Physicochemical, Pharmacokinetic and Pharmacodynamic Evaluation of Liposomal Tacrolimus (FK 506) in Rats, Pharm. Res., 12: 1055-1059 (1995). PMID: 7494802
333. Ko HC, Almon RR, and Jusko WJ, Effect of Corticosteroid Binding Globulin on the Pharmacokinetics of Prednisolone in Rats, Pharm. Res., 12: 902-904 (1995). PMID: 7667198
334. Lee M-L, Pyszczynski N, and Jusko WJ, Combined Inhibition Effects of Tacrolimus and Methylprednisolone on In Vitro Human Lymphocyte Proliferation, Immunopharmacol. Immunotoxicol. 17: 335-345 (1995). PMID: 7544367
335. Fasanmade AA and Jusko WJ, Effect of Halofantrine and its Desbutyl Metabolite on Lymphocyte Proliferation Dynamics, Life Sci. Pharmacol. Letters, 57: 175-180 (1995). PMID: 7564875
336. Szefler SJ, Bender BG, Jusko WJ, Lanier BQ, Lemanske RF, Skoner DP, and Stempel DA, Evolving Role of Theophylline in Treatment of Chronic Childhood Asthma, J. Peds. 127: 176-185 (1995). PMID: 7636640
337. Milad MA, Ludwig EA, Ane S, Middleton E, and Jusko WJ, Pharmacodynamic Model for Joint Exogenous and Endogenous Corticosteroid Suppression of Lymphocyte Trafficking, J. Pharmacokin. Biopharm., 22: 469-480 (1994). PMID: 7473077
338. Fasanmade, AA, Jusko WJ, Optimizing Whole Blood Lymphocyte Proliferation in the Rat, J. Immun. Meth., 184: 163-167 (1995). PMID: 7658020
339. DuBois DC, Xu Z-X, McKay L, Almon RR, Pyszczynski N, and Jusko WJ, Differential Dynamics of Receptor Down-Regulation and Tyrosine Aminotransferase Induction Following Glucocorticoid Treatment, J. Steroid Biochem. Mol. Biol., 54: 237-243 (1995). PMID: 7577705
340. Jusko WJ, Ko HC, and Ebling WF, Convergence of Indirect and Direct Pharmacodynamic Response Models, J. Pharmacokin. Biopharm., 23: 5-8 (1995). PMID: 8576844
341. Xu Z-X, Sun Y-N, Dubois DC, Almon RR, Jusko WJ, Third-Generation Model for Corticosteroid Pharmacodynamics: Roles of Glucocorticoid Receptor mRNA and Tyrosine Aminotransferase mRNA in Rat Liver, J. Pharmacokin Biopharm 23: 163-181 (1995). PMID: 8719235
342. Van Griensven, JMTh, Jusko WJ, Lemkes HHPJ, Kroon R, Chiang ST, and AF Cohen, Tolrestat Pharmacokinetic and Pharmacodynamic Effects on Red Blood Cell Sorbitol Levels in Normal Volunteers and in Patients with Insulin-Dependent Diabetes, Clin. Pharmacol. Ther., 58: 631-640 (1995). PMID: 8529328
343. Nash RA, Etzioni R, Storb R, Furlong T, Gooley T, Anasetti C, Appelbaum FR, Doney K, Martin P, Slattery J, Sullivan K, van der Jagt R, Witherspoon R, Jusko WJ, Zager RA, and Deeg MJ, Tacrolimus (FK506) Alone or in Combination with Methotrexate or Methylprednisolone for the Prevention of Acute Graft-Versus-Host Disease After Marrow Transplantation from HLA-Matched Siblings: A Single-Center Study, Blood, 85: 3746-3753 (1995). PMID: 7540071
344. Jusko WJ, Analysis of Tacrolimus (FK506) in Relation to Therapeutic Drug Monitoring, Ther Drug Monit, 17: 596-601 (1995). PMID: 8588227
345. Jusko WJ, Thomson AW, Fung J, McMaster P, Wong SH, Zylber-Katz E, Christians U, Winkler M, Fitzsimmons WE, Lieberman R, McBride J, Kobayashi M, Warty V, and Soldin SJ, Consensus Document: Therapeutic Monitoring of Tacrolimus (FK-506), Ther. Drug Monit., 17: 606-614 (1995). PMID: 8588229
346. Cheng H and Jusko WJ, Disposition Decomposition Analysis for Pharmacodynamic Modeling of the Link Compartment, Biopharm. Drug Disp., 17: 117-124 (1996). PMID: 8907718
347. Mishina EV and Jusko WJ, Liposomal Methylprednisolone in Rats: Dose-Proportionality and Chronic-Dose Pharmacokinetics/Dynamics, Pharm. Res., 13: 141-145 (1996). PMID: 8668664
348. Jusko WJ, Pharmacokinetics and Receptor-Mediated Pharmacodynamics of Corticosteroids, Toxicol. 102: 189-196 (1995). PMID: 7482553
349. Slayter KL, Ludwig EA, Lew KH, Middleton Jr, E, Ferry JJ, and Jusko WJ, Oral Contraceptive Effects on Methylprednisolone Pharmacokinetics and Pharmacodynamics, Clin. Pharmacol. Ther., 59: 312-321 (1996). PMID: 8653994
350. Jusko WJ, Physiologically Based Models in Pharmacodynamics, Ch 2.7 in "Pharmacokinetic/Pharmacodynamic Analysis: Accelerating Drug Discovery and Development", J Schlegel, Ed., Int. Bus. Comm. Inc., Southborough MA, pp.1-20 (1996).
351. Ferron GM, Rochdi M, Jusko WJ, and Scherrmann J-M, Oral Absorption Characteristics and Pharmacokinetics of Colchicine in Healthy Volunteers after Single and Multiple Doses, J. Clin. Pharmacol., 36: 874-883 (1996). PMID: 8930773
352. Meno-Tetang Guy ML, Hon YY, and Jusko WJ, Synergistic Interaction Between Dehydroepiandrosterone and Prednisolone in the Inhibition of Rat Lymphocyte Proliferation, Immunopharm. Immunotoxicol 18: 443-456 (1996). PMID: 8872495
353. Sharma A and Jusko WJ, Characterization of Four Basic Models of Indirect Pharmacodynamic Responses, J. Pharmacokin. Biopharm. 24: 611-635 (1996). PMID: 9300353
354. Jusko WJ, Ferron GM, Mis SM, Kahan BD, and Zimmerman JJ, Pharmacokinetics of Prednisolone During Administration of Sirolimus in Patients with Renal Transplants, J. Clin. Pharmacol., 36: 1100-1106 (1996). PMID: 9013365
355. Ferron GM, Mishina EV, Zimmerman JJ, and Jusko WJ, Population Pharmacokinetics of Sirolimus in Kidney Transplant Patients, Clin. Pharmacol. Ther., 61: 416-428 (1997). PMID: 9129559
356. Cheng H, Gong Y, and Jusko WJ, A Computer Program Using Disposition Decomposition Analysis in Pharmacodynamics, Biopharm. Drug Dispos., 18: 9-15 (1997). PMID: 9008265
357. Chow FS, Piekoszewski W, and Jusko WJ, Effect of Hematocrit and Albumin Concentration on Hepatic Clearance of Tacrolimus (FK 506) During Rabbit Liver Perfusion, Drug Met. Disp., 25: 610-616 (1997). PMID: 9152601
358 Sharma A and Jusko WJ, Indirect Pharmacodynamic Models for Tolerance and Rebound Phenomena, Chap. 3.2 In: Pharmacokinetic/Pharmacodynamic Analysis II, Int. Bus. Commun. Inc., Southborough, MA (1997).
359. Krzyzanski W and Jusko WJ, Application of Moment Analysis to the Sigmoid Effect Model for Drug Administered Intravenously, Pharmaceut. Res., 14: 949-952 (1997). PMID: 9244156
360. Ko HC, Jusko WJ, and Ebling WF, Nonlinear Perpendicular Least Squares Regression in Pharmacodynamics, Biopharm. Drug Disp., 18: 711-716 (1997). PMID: 9373727
361. Krzyzanski W and Jusko WJ, Mathematical Formalism for the Properties of Four Basic Models of Indirect Pharmacodynamic Responses, J.

Pharmacokin. Biopharm: 25: 107-123 (1997). PMID: 9353696
362. McKay LI, DuBois DC, Sun Y-N, Almon RR, and Jusko WJ, Corticosteroid Effects in Skeletal Muscle: Gene Induction/Receptor Autoregulation, Muscle & Nerve, 20: 1318-1320 (1997). PMID: 9324091
363. Ferron GM, Conway WD, and Jusko WJ, Lipophilic Benzamide and Anilide Derivatives as High-Performance Liquid Chromatography Internal Standards: Application to Sirolimus (Rapamycin) Determination, J Chrom B., 703: 243-251 (1997). PMID: 9448082
364. Krzyzanski W and Jusko WJ, Integrated Functions for Four Basic Models of Indirect Pharmacodynamic Response, J. Pharm. Sci., 87: 67-72 (1998). PMID: 9452970
365. Ferron GM and Jusko WJ, Species Differences in Sirolimus Stability in Humans, Rabbits and Rats, Drug Metab. Disp., 26: 83-84 (1998). PMID: 9443858
366. Sharma A and Jusko WJ, Characteristics of Indirect Pharmacodynamic Models and Applications to Clinical Drug Responses, Brit. J. Clin. Pharmacol., 45: 229-239 (1998). PMID: 9517366
367. Segal JL, Maltby BF, Langdorf MI, Jacobson R, Brunnemann SR, and Jusko WJ, Methylprednisolone Disposition Kinetics in Humans with Acute Spinal Cord Injury, Pharmacotherapy, 18: 16-22 (1998). PMID: 9469676
368. Sun Y-N and Jusko WJ, Transit Compartments versus Gamma Distribution Function to Model Signal Transduction Processes in Pharmacodynamics, J. Pharm. Sci., 87: 732-737 (1998). PMID: 9607951
369. Ferron GM, Pyszczynski NA, and Jusko WJ, Gender-Related Assessment of Cyclosporine/Prednisolone/Sirolimus Interactions in Three Human Lymphocyte Proliferation Assays, Transplantation, 65: 1203-1209 (1998). PMID: 9603169
370. Ferron GM and Jusko WJ, Species- and Gender-Related Differences in Cyclosporine/Prednisolone/Sirolimus Interactions in Whole Blood Lymphocyte Proliferation Assays, J. Pharmacol. Exp. Ther., 286: 191-200 (1998). PMID: 9655860
371. Sharma A, Ebling WF, and Jusko WJ, Precursor-Dependent Indirect Pharmacodynamic Response Model for Tolerance and Rebound Phenomena, J. Pharm. Sci., 87: 1577-1584 (1998). PMID: 10189270
372. Gobburu JVS and Jusko WJ, Role of Dosage Regimen in Controlling Indirect Pharmacodynamic Responses, Adv. Drug Del. Rev., 33: 221-233 (1998). PMID: 10837662
373. Gobburu JVS, TenHoor C, Rogge MC, Frazier DE, Thomas D, Benjamin C, Hess DM, and Jusko WJ, Pharmacokinetics/Dynamics of 5c8, a Monoclonal Antibody to CD154 (CD40 Ligand): Suppression of an Immune Response in Monkeys, J. Pharmacol. Exp. Ther., 286: 925-930 (1998). PMID: 9694951
374. Gumbhir-Shah K, Kellerman, DJ, DeGraw S, Koch P, and Jusko WJ, Pharmacokinetic-Pharmacodynamic Characteristics and Safety of Inhaled Albuterol Enantiomers in Healthy Volunteers, J. Clin. Pharmacol., 38: 1096-1106 (1998). PMID: 11301561
375. Sharma A, Slugg PH, Hammett JL, and Jusko WJ, Estimation of Oral Bioavailability of a Long Half-Life Drug in Healthy Subjects, Pharm. Res., 15: 1782-1786 (1998). PMID: 9834003
376. Sun Y-N, DuBois DC, Almon RR, and Jusko WJ, Fourth-Generation Model for Corticosteroid Pharmacodynamics: A Model for Methylprednisolone Effects on Receptor/Gene-Mediated Glucocorticoid Receptor Down-Regulation and Tyrosine Aminotransferase Induction in Rat Liver, J. Pharmacokin. Biopharm., 26: 289-316 (1998). PMID: 10098101
377. Krzyzanski W and Jusko WJ, Characterization of Pharmacodynamic Recession Slopes for Direct and Indirect Response Models, J. Pharmacokin. Biopharm., 26: 409-435 (1998). PMID: 10214560
378. Radwanski E, Chakraborty A, Van Wart S, Huhn RD, Cutler DL, Affrime MB, and Jusko WJ, Pharmacokinetics and Leukocyte Responses of Recombinant Human Interleukin-10, Pharm. Res., 15: 1895-1901 (1998). PMID: 9892475
379. Krzyzanski W and Jusko WJ, Mathematical Formalism and Characteristics of Four Basic Models of Indirect Pharmacodynamic Responses for Drug Infusions, J. Pharmacokin. Biopharm., 26: 385-408 (1998). PMID: 10214559
380. Ferron GM and Jusko WJ, Pharmacokinetic and Pharmacoimmunodynamic Interactions between Prednisolone and Sirolimus in Rabbits, Pharm. Res., 15: 1888-1894 (1998). PMID: 9892474
381. Sharma A, Slugg PH, Hammett JL, and Jusko WJ, Clinical Pharmacokinetics and Pharmacodynamics of a New Squalene Synthase Inhibitor, BMS-188494, in Healthy Volunteers, J. Clin. Pharmacol., 38: 1116-1121 (1998). PMID: 11301563
382. Flores-Murrieta FJ, Ko HC, Flores-Acevedo DM, Lopez-Munoz FJ, Jusko WJ, Sale ME, and Castaneda-Hernandez G, Pharmacokinetic-Pharmacodynamic Modeling of Tolmetin Antinociceptive Effect in the Rat Using an Indirect Response Model: A Population Approach, J. Pharmacokin. Biopharm., 26: 547-557 (1998). PMID: 10205770
383. Sun Y-N, DuBois DC, Almon RR, Pyszczynski NA, and Jusko WJ, Dose-Dependence and Repeated-Dose Studies for Receptor/Gene Mediated Pharmacodynamics of Methylprednisolone on Glucocorticoid Receptor Down-Regulation and Tyrosine Aminotransferase Induction in Rat Liver, J. Pharmacokin. Biopharm., 26: 619-648 (1998). PMID: 10485078
384. Krzyzanski W and Jusko WJ, Caution in Use of Empirical Equations for Pharmacodynamic Indirect Response Models, J. Pharmacokin. Biopharm., 26: 735-741 (1998). PMID: 10485083
385. Meno-Tetang GML, Gobburu JVS, and Jusko WJ, Influence of Gender on Prednisolone Effects on Whole Blood T-Cell Deactivation and Trafficking in Rats, J. Pharm. Sci., 88: 46-51 (1999). PMID: 9874701
386. Meno-Tetang, GML, Hon YY, VanWart S, and Jusko WJ, Pharmacokinetic and Pharmacodynamic Interactions Between Dehydroepiandrosterone and Prednisolone in the Rat, Drug Met. Drug Interact., 15: 51-70 (1999). PMID: 10707113
387. Sun Y-N, McKay LI, DuBois DC, Jusko WJ, and Almon RR, Pharmacokinetic-Pharmacodynamic Models for Corticosteroid Receptor Down-Regulation and Glutamine Synthetase Induction in Rat Skeletal Muscle by a Receptor/Gene-Mediated Mechanism, J. Pharmacol. Exper. Ther., 288: 720-728 (1999). PMID: 9918581
388. Chakraborty A, Blum RA, Cutler DL, and Jusko WJ, Pharmacoimmunodynamic Interactions of IL-10 and Prednisone in Healthy Volunteers, Clin. Pharmacol. Ther., 65: 304-318 (1999). PMID: 10096263
389. Sharma A, Jusko WJ, Fulmor IE, Norton J, Uderman HD, and Salazar DE, Clinical Pharmacokinetics and Pharmacodynamics of Avitriptan During Intravenous Administration in Healthy Subjects, J. Clin. Pharmacol., 39: 685-694 (1999). PMID: 10392323
390. Chakraborty A, Blum RA, Mis SM, Cutler DL, and Jusko WJ, Pharmacokinetic and Adrenal Interactions of IL-10 and Prednisone in Healthy Volunteers, J. Clin. Pharmacol., 39: 624-635 (1999). PMID: 10354967
391. Sun Y-N, Lee HJ, and Almon RJ, A Pharmacokinetic/Pharmacodynamic Model for Recombinant Human Growth Hormone (rhGH) Effects on Induction of Insulin-Like Growth Factor I (IGF-I) in Monkeys, J. Pharmacol. Exp. Ther., 289: 1523-32 (1999). PMID: 10336548
392. Ferron GM and Jusko WJ, Clinical Pharmacokinetics and Pharmacodynamics of Glucocorticoids in Transplant Patients, Graft, 2: 182-186 (1999).
393. Ferron GM, Pyszczynski NA, and Jusko WJ, Pharmacokinetic and Pharmacoimmunodynamic Interactions Between Prednisolone and Sirolimus

in Adrenalectomized Rats, J. Pharmacokin. Biopharm., 27: 1-21 (1999). PMID: 10533695

394. Krzyzanski W, Chakraborty A, and Jusko WJ, Algorithm for Application of Fourier Analysis for Biorhythmic Baselines of Pharmacodynamic Indirect Response Models, Chronobiol. Internat., 17: 77-93 (2000). PMID: 10672436
395. Chakraborty A, Krzyzanski W, and Jusko WJ, Mathematical Modeling of Circadian Cortisol Concentrations Using Indirect Response Models: Comparison of Several Methods, J. Pharmacokin. Biopharm., 27: 23-43 (1999). PMID: 10533696
396. Gumbhir-Shah K, Kellerman DJ, DeGraw S, Koch P, and Jusko WJ, Pharmacokinetics and Pharmacodynamics of Cumulative Single Doses of Inhaled Albuterol Enantiomers in Asthmatic Subjects, Pulm. Pharmacol. Ther., 12: 353-362 (1999). PMID: 10587476
397. Imani S, Jusko WJ, and Steiner R, Diltiazem Retards the Metabolism of Oral Prednisone with Effects on T-Cell Markers, Pediatr. Transplant., 3: 126-130 (1999). PMID: 10389134
398. Davis CB, Tobia LP, Kwok DC, Oishi CM, Kheterpal N, Hebburn TW, Benincosa LJ, Chow FS, and Jusko WJ, Accumulation of Antibody-Target Complexes and the Pharmacodynamics of Clotting after Single Intravenous Administration of Humanized Anti-Factor IX Monoclonal Antibody to Rats, Drug Delivery, 6: 171-179 (1999).
399. Gobburu JVS, Agerso H, Jusko WJ, and Ynddal L, Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers, Pharmaceut. Res., 16: 1412-1416 (1999). PMID: 10496658
400. Sun Y-N and Jusko WJ, Role of Baseline Parameters in Determining Indirect Pharmacodynamic Responses, J. Pharm. Sci., 88: 987-990 (1999). PMID: 10514344
401. Fasanmade AA and Jusko WJ, Immunodynamics of Methylprednisolone Induced T-Cell Trafficking and Deactivation Using Whole Blood Lymphocyte Proliferation Techniques in the Rat, Biopharm. Drug Disp., 20: 255-261 (1999). PMID: 10594870
402. Benincosa LJ, Chow F-S, Tobia LP, Kwok DC, Davis CB, and Jusko WJ, Pharmacokinetics and Pharmacodynamics of a Humanized Monoclonal Antibody to Factor IX in Cynomolgus Monkeys, J. Pharmacol. Exp. Ther., 292: 810-816 (2000). PMID: 10640322
403. Krzyzanski W, Ramakrishnan R, and Jusko WJ, Basic Pharmacodynamic Models for Agents which Alter Production of Natural Cells, J. Pharmacokin. Biopharm., 27: 467-489 (2000). PMID: 10948694
404. Chow F-S, Sharma A, and Jusko WJ, Modeling Interactions between Adrenal Suppression and T-Helper Lymphocyte Trafficking During Multiple-Dosing of Methylprednisolone, J. Pharmacokin. Biopharm., 27: 559-575 (1999). PMID: 11153446
405. Gabrielsson J, Jusko WJ, and Alari L, Modeling of Dose-Response-Time Data: Four Examples of Generating Kinetic Functions from Response Profiles, Biopharm. Drug Disp., 21: 41-52 (2000). PMID: 11100906
406. Levy G, Zamacona MK, and Jusko, WJ. Developing Compliance Instructions for Drug Labeling, Clin. Pharmacol. Ther., 68: 586-591 (2000). PMID: 11180017
407. Wyska E and Jusko WJ, Approaches to Pharmacokinetic/Pharmacodynamic Modeling during Pregnancy, Seminars in Perinatology, 25: 124-132 (2001). PMID: 11453607
408. Puchalski TA, Krzyzanski W, Blum RA, and Jusko WJ. Pharmacodynamic Modeling of Lansoprazole Using an Indirect Irreversible Response Model, J. Clin. Pharmacol., 41: 251-258 (2001). PMID: 11269565
409. Krzyzanski W and Jusko WJ, Indirect Pharmacodynamic Models for Responses with Multicompartmental Distribution or Polyexponential Disposition, J. Pharmacokin. Pharmacodyn., 28: 57-78 (2001). PMID: 11253614
410. Mager DE and Jusko WJ, Pharmacodynamic Modeling of Time-Dependent Transduction Systems, Clin. Pharmacol. Ther., 70: 210-216 (2001). PMID: 11557908
411. Jusko WJ, Relationship of Dose- and Time-Dependent Corticosteroid Responses to Receptor Turnover, Proceedings of a Workshop on "The Anti-Asthmatic Actions and Selectivity of Inhaled Steroids", Chap 5, pp. 95-112, Eds. RP Schleimer, P O'Bryne, SJ Szefler, and R Brattsand, Marcel Dekker Inc, New York (2001).
412. Magee MH, Blum RA, Lates CD, and Jusko WJ, Prednisolone Pharmacokinetics and Pharmacodynamics in Relation to Sex and Race, J. Clin. Pharmacol., 41: 1180-1194 (2001). PMID: 11697751
413. Meno-Tetang G, Blum RA, Schwartz KE, Jusko WJ, Effects of Oral Prasterone (Dehydroepiandosterone) on Single-Dose Pharmacokinetics of Oral Prednisone and Cortisol Suppression in Normal Women, J. Clin. Pharmacol., 41: 1195-1205 (2001). PMID: 11697752
414. Ramakrishnan R and Jusko WJ, Interactions of Aspirin and Salicylic Acid with Prednisolone for Inhibition of Lymphocyte Proliferation, Internat. Immunopharmacol., 1: 2035-2042 (2001). PMID: 11606034
415. Chakraborty A and Jusko WJ, Pharmacodynamic Interaction of Recombinant Interleukin-10 and Prednisolone Using In Vitro Whole Blood Lymphocyte Proliferation, J. Pharm. Sci., 91: 1334-1342 (2002). PMID: 11977109
416. Chow F-S, Benincosa LJ, Sheth SB, Wilson D, Davis CB, Minthorn EA, Jusko WJ, Pharmacokinetic and Pharmaco-dynamic Modeling of Humanized Anti-Factor IX Antibody (SB 249417) in Humans, Clin. Pharm. Ther., 71: 235-245 (2002). PMID: 11956506
417. Ramakrishnan R, Dubois D, Almon RA, Pyszczynski NA, and Jusko WJ, Pharmacodynamics and Pharmacogenomics of Methylprednisolone during 7-Day Infusion in Rats, J. Pharmacol. Exper. Ther., 300: 245-256 (2002). PMID: 11752123
418. Magee MH, Blum RA, Lates CD, and Jusko WJ, Integrated Pharmacokinetic/Pharmacodynamic Model for Prednisolone Inhibition of Ex Vivo Whole Blood Lymphocyte Proliferation, Brit. J. Clin. Pharmacol., 53: 474-484 (2002). PMID: 11994053
419. Mager DE and Jusko WJ, General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition, J. Pharmacokin. Biopharm., 28: 507-532 (2001). PMID: 11999290
420. Ramakrishnan R, DuBois D, Almon RA, Pyszczynski NA, and Jusko WJ, Fifth-Generation Model for Corticosteroid Pharmacodynamics: Steady-State Receptor Down-Regulation and Enzyme Induction Patterns During Seven-Day Continuous Infusion of Methylprednisolone in Rats, J. Pharmacokin. Pharmacodyn., 29: 1-24 (2002). PMID: 12194533
421. Bernstein SH, Jusko WJ, Krzyzanski, W., Nichols J, and Wetzler M, Pharmacodynamic Modeling of Thrombopoietin, Platelet and Megakarocyte Dynamics in Patients with Acute Myeloid Leukemia Undergoing Dose Intensive Chemotherapy, Cancer Res., J. Clin. Pharmacol., 42: 501-511 (2002). PMID: 12017344
422. Zimmerman JJ, Harper D, Getsy J, Jusko WJ, Pharmacokinetic Interactions Between Sirolimus and Microemulsion Cyclosporine When Orally Administered Jointly and 4 Hours Apart in Healthy Volunteers, J. Clin. Pharmacol., 43: 1168-76 (2003). PMID: 14517200
423. Li H, Meno-Tetang GML, Chiba K, Arima N, Heining P, Jusko WJ, Pharmacokinetics and Cell Trafficking Dynamics of FTY720 in Cynomolgus Monkeys Following Single Oral and Intravenous Doses, J. Pharmacol. Exp. Ther., 301: 519-526 (2002). PMID: 11961052
424. Almon RA, Dubois DC, Brandenburg EH, Shi W, Zhang S, Straubinger RM, and Jusko WJ, Pharmacodynamics and Pharmacogenomics of Diverse Receptor-Mediated Effects of Methylprednisolone in Rats using Microarray Analysis, J. Pharmacokin. Pharmacodyn., 29: 103-129 (2002). PMID: 12361239

425. Mager DE and Jusko WJ, Quantitative Structure-Pharmacokinetic/Pharmacodynamic Relationships of Corticosteroids in Man, J. Pharm. Sci., 91: 2441-2451 (2002). PMID: 12379930
426. Booker BM, Magee M, Blum RA, Lates CD, and Jusko WJ, Pharmacokinetic and Pharmacodynamic Interactions between Diltiazem and Methylprednisolone in Healthy Volunteers, Clin. Pharmacol. Ther. 72: 370-382 (2002). PMID: 12386639
427. Krzyzanski W and Jusko WJ, Multiple-Pool Cell Lifespan Model of Hematologic Effects of Anticancer Agents, J. Pharmacokin. Pharmacodyn., 29: 311-337 (2002). PMID: 12518707
428. Levy G, Mager DE, Cheung WK, and Jusko WJ, Comparative Pharmacokinetics of Coumarin Anticoagulants L: Physiologic Modeling of S-Warfarin in Rats and Pharmacologic Target-Mediated Disposition in Man, J. Pharm. Sci., 92: 985-994 (2003). PMID: 12712418
429. Mager DE, Pyszczynski N, and Jusko WJ, Integrated QSPR – Pharmacodynamic Model of Genomic Effects of Several Corticosteroids, J. Pharm. Sci., 92: 881-889 (2003). PMID: 12661073
430. Mager DE and Jusko WJ, Receptor-Mediated Pharmacokinetic/Pharmacodynamic Model of Interferon-Beta in Man, Pharm. Res., 19: 1537-1543 (2002). PMID: 12425473
431. Jeng S, Chanchairujira T, Jusko WJ, and Steiner R, Prednisone Metabolism in Recipients of Kidney or Liver Transplants and in Lung Recipients Receiving Ketoconazole, Transplantation, 75: 792-795 (2003). PMID: 12660503
432. Petersen KB, Jusko WJ, Rasmussen M, and Schmiegelow K, Population Pharmacokinetics of Prednisolone in Children with Acute Lymphoblastic Leukemia, Cancer Chemother. Pharmacol., 51: 465-473 (2003). PMID: 12698270
433. Ramakrishnan R, Cheung WK, Farrell F, Jolliffe L, and Jusko WJ, Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin after Intravenous and Subcutaneous Single Dose Administrations in Cynomolgous Monkeys, J. Pharmacol. Exp. Ther., 306: 324-331 (2003). PMID: 12676891
434. Mager DE, Moledina N, and Jusko WJ, Relative Immunosuppressive Potency of Therapeutic Corticosteroids Measured by Whole Blood Lymphocyte Proliferation, J. Pharm. Sci., 92: 1521-1525 (2003). PMID: 12820156
435. Mager DE, Wyska E, Jusko WJ, Diversity of Mechanism-Based Pharmacodynamic Models, Drug Met. Disp., 31: 510-518 (2003). PMID: 12695336
436. Almon RR, DuBois DC, Pearson KE, Stephan DA, and Jusko WJ, Gene Arrays and Temporal Patterns of Drug Response: Corticosteroid Effects on Rat Liver, Functional & Integrative Genomics, 3: 171-179 (2003). PMID: 12928814
437. Mager DE, Neuteboom B, Efthymiopoulos C, Munafo A, and Jusko WJ, Receptor-Mediated Pharmacokinetics and Pharmacodynamics of Interferon-β1a Following Intravenous and Subcutaneous Dosing in Monkeys, J. Pharmacol. Exp. Ther., 306: 262-270 (2003). PMID: 12660309
438. Jin JY, Almon RR, Dubois DC, and Jusko WJ, Modeling of Corticosteroid Pharmacogenomics in Rat Liver Using Gene Microarrays, J. Pharmacol. Exp. Ther., 307: 93-109 (2003) [*featured on cover of November 2003 issue of journal*]. PMID: 12808002
439. Mager DE, Lin SX, Blum RA, Lates CD, and Jusko WJ, Dose Equivalency Evaluation of Major Corticosteroids I. Pharmacokinetics and Cell Trafficking and Cortisol Dynamics, J. Clin. Pharmacol., 43: 1216-1227 (2003). PMID: 14551176
440. Jin JY, Dubois DC, Almon RR, and Jusko WJ, Receptor/Gene-Mediated Pharmacodynamic Effects of Methylprednisolone on Phosphoenolpyruvate Carboxylase Regulation in Rat Liver, J. Pharmacol. Exper. Ther., 309: 328-339 (2004). PMID: 14722324
441. Samtani MN, Schwab M, Nathanielsz PW, and Jusko WJ, Stabilization and HPLC Analysis of Betamethasone Sodium Phosphate in Plasma, J. Pharm. Sci., 93: 726-732 (2004). PMID: 14762910
442. Almon RR, Chen J, Snyder G, Dubois DC, Jusko WJ, and Hoffman EP. In Vivo Multi-Tissue Corticosteroid Microarray Time Series Available Online at Public Expression Profile Resource (PEPR). Pharmacogenomics, 4: 791-799 (2003). PMID: 14596642
443. Chen J, Zhao P, Massaro D, Clerch LB, Almon RR, Dubois DC, Jusko WJ, and Hoffman EP, The PEPR GeneChip Data Warehouse, and Implementation of a Dynamic Time Series Query Tool (SGQT) with Graphical Interface, Nucleic Acids Research, 32: D578-D581 (2004). PMID: 14681485
444. Jusko WJ, Jin JY, Dubois DC, and Almon RR. Pharmacodynamics and Pharmacogenomics of Corticosteroids: Microarray Studies, In: Advanced Methods of Pharmacokinetic and Pharmacodynamics Systems Analysis, Volume 3, D.Z. D'Argenio, Editor, Kluwer Academic Publishers, Boston, pp. 85-103 (2004).
445. Smith PF, Bullock JM, Booker BM, Haas CE, Berenson C, and Jusko WJ, Induction of Imatinib Metabolism by Hypericum Perforatum, Blood, 104: 1229-30 (2004). PMID: 15294859
446. Lima JJ, Matsushima N, Kissoon N, Wang J, Sylvester JE, Jusko WJ, Modeling the Metabolic Effects of Terbutaline in β2 Adrenergic Receptor Diplotypes, Clin. Pharmacol. Ther., 76: 27-37 (2004). PMID: 15229461
447. Almon RR, DuBois DC, Piel WH, Jusko, WJ. The Genomic Response of Skeletal Muscle to Methylprednisolone Using Microarrays: Tailoring Data Mining to the Structure of the Pharmacogenomic Time Series, Pharmacogenomics, 5: 525-552 (2004). PMID: 15212590
448. Lepist E-I, Jusko WJ. Modeling and Allometric Scaling of s(+)Ketoprofen Pharmacokinetics and Pharmacodynamics: A Retrospective Analysis. J. Vet. Pharmacol. Ther., 27: 211-218 (2004). PMID: 15305849
449. Earp J, Krzyzanski W, Chakraborty A, Zamacona MK, and Jusko WJ, Assessment of Drug Interactions Relevant to Pharmacodynamic Indirect Response Models, J. Pharmacokin. Pharmacodyn., 31: 345-380 (2004). PMID: 15669772
450. Kamal MA and Jusko WJ, Interactions of Prednisolone and Other Immunosuppressants Used in Dual Treatment of Systemic Lupus Erythematosus in Lymphocyte Proliferation Assays, J. Clin. Pharmacol., 44: 1034-1045 (2004). PMID: 15317831
451. Ramakrishnan R, Cheung WK, Wacholtz MC, Minton N, and Jusko WJ, Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin after Single and Multiple Doses in Healthy Volunteers, J. Clin. Pharmacol., 44: 991-1002 (2004). PMID: 15317827
452. Smith PF, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ, The Influence of St. John's Wort on the Pharmacokinetics and Protein Binding of Imatimib Mesylate, Pharmacotherapy, 24: 1508-1514 (2004). PMID: 15537555
453. Samtani MN, Nathanielsz PW, Schwab M, and Jusko WJ, Area/Moment and Compartmental Modeling of Pharmacokinetics during Pregnancy: Applications to Maternal/Fetal Exposures to Corticosteroids in Sheep and Rats, Pharm. Res., 21: 2279-2292 (2004). PMID: 15648260
454. Chakraborty A, Yeung S, Pyszczynski NA, and Jusko WJ, Pharmacodynamic Interactions between Recombinant Mouse Interleukin-10 and Prednisolone Using a Mouse Endotoxemia Model, J. Pharm. Sci., 94: 590-603 (2005). PMID: 15666292
455. Almon RR, DuBois DC, Jin JY, Jusko WJ, Pharmacogenomic Responses of Rat Liver to Methylprednisolone: An Approach to Mining a Rich Microarray Time Series, The AAPS Journal, 7: E156-E194 (2005). PMID: 16146338
456. Mager DE, Neuteboom B, Jusko WJ, Pharmacokinetics and Pharmacodynamics of Pegylated IFN-β1a Following Subcutaneous Administration in Monkeys, Pharm. Res., 22: 58-61 (2005). PMID: 15771230

457. Chow F-S and Jusko WJ, Immunosuppressive Interactions among Calcium Channel Antagonists and Selected Corticosteroids and Macrolides Using Human Whole Blood Lymphocytes, Drug Metab. & Pharmacokin., 19: 413-421 (2004). PMID: 15681895
458. Samtani M and Jusko WJ, Comparison of Dexamethasone Pharmacokinetics in Female Rats after Intravenous and Intramuscular Administration, Biopharm. & Drug Dispos., 26: 85-91 (2005). PMID: 15654687
459. Almon RR, DuBois DC, Jin JY, Jusko WJ, Temporal Profiling of the Transcriptional Basis for the Development of Corticosteroid-Induced Insulin Resistance in Rat Muscle, J. Endocrinol., 184: 219-232 (2005). PMID: 15642798
460. Jusko WJ, Guidelines for Collection and Analysis of Pharmacokinetic Data, Burton ME, Shaw LM, Schentag JJ, Evans WE, Editors, Applied Pharmacokinetics & Pharmacodynamics, 4th Edition, Lippincott Williams & Wilkins, Philadelphia, pp 9-29 (2005).
461. Samtani M, Lohle M, Grant A, Nathanielsz PW, and Jusko WJ, Betamethasone Pharmacokinetics after Two Prodrug Formulations in Sheep: Implications for Antenatal Corticosteroid Use, Drug Metab. Dispos., 33: 1124-1130 (2005). PMID: 15860658
462. Krzyzanski W, Jusko WJ, Wacholtz, Minton N, Cheung WK, Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin after Multiple Subcutaneous Doses in Healthy Subjects, Eur. J. Pharm. Sci., 26: 295-306 (2005). PMID: 16102948
463. Almon RR, Lai W, DuBois DC, Jusko WJ, Corticosteroid Regulated Genes in Rat Kidney: Mining Time Series Array Data, Am. J. Physiol., Endocrinology and Metabolism, 289: E870-E882 (2005). PMID: 15985454
464. Ruixo JJP, Kimko HC, Chow AT, Piotrovsky V, Krzyzanski W, and Jusko WJ, Population Cell Lifespan Models for Effects of Drugs Following Indirect Mechanisms of Action, J. Pharmacokin. Pharmacodyn., 32: 767-793 (2005). PMID: 16328102
465. Gordi T, Xie R, and Jusko WJ, Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modelling of the Antimalarial Effect of Artemisinin, Brit. J. Clin. Pharmacol., 60: 594-604 (2005). PMID: 16305583
466. Krzyzanski W, Woo S, and Jusko WJ, Pharmacodynamic Models for Agents that Alter Production of Natural Cells with Various Distributions of Lifespans, J. Pharmacokin. Pharmacodyn., J. Pharmacokin. Pharmacodyn., 33: 125-166 (2006). PMID: 16565883
467. Samtani M and Jusko WJ, Stability of Dexamethasone Sodium Phosphate in Rat Plasma, Int. J. Pharmaceutics, 301: 262-266 (2005). PMID: 16054309
468. Yao Z, Krzyzanski W, and Jusko WJ, Assessment of Basic Indirect Response Models with Physiological Limits, J. Pharmacokin.Pharmacodyn., 33: 167-193 (2006). PMID: 16547797
469. Yao Z, DuBois DC, Almon RA, and Jusko WJ, Modeling Circadian Rhythms of Glucocorticoid Receptor and Glutamine Synthetase Expression in Rat Skeletal Muscle, Pharm. Res., 23: 670-679 (2006). PMID: 16673181
470. Samtani M, Pyszczynski NA, DuBois D, Almon RR, and Jusko WJ, Modeling Glucocorticoid-Mediated Fetal Lung Maturation I. Temporal Patterns of Corticosteroids in Rat Pregnancy, J. Pharmacol. Exp. Ther., 317: 117-126 (2006). PMID: 16371449
471. Samtani M, Pyszczynski NA, DuBois D, Almon RR, and Jusko WJ, Modeling Glucocorticoid-Mediated Fetal Lung Maturation II. Temporal Patterns of Gene Expression in Fetal Rat Lung, J. Pharmacol. Exp. Ther., 317: 127-138 (2006). PMID: 16371448
472. Qu J, Jusko WJ, and Straubinger RM, Utility of Cleavable Isotope-Coded Affinity-Tagged Reagents for Quantification of Low-Copy Proteins Induced by Methylprednisolone Using Liquid Chromatography/Tandem Mass Spectrometry, Anal. Chem., 78: 4543-4552 (2006). PMID: 16808464
473. Hon YY, Jusko WJ, Zhou HH, Chen GL, Guo D, Zhou G, Spratlin VE, Jann MW, Endogenous Histamine and Cortisol Levels in Subjects with Different Histamine N-Methyltransferase C314T Genotypes, Mol. Diag. Ther., 10: 109-114 (2006). PMID: 16669609
474. Hon YY, Jusko WJ, Spratlin VE, and Jann MW, Altered Methylprednisolone Pharmacodynamics in Healthy Subjects with Histamine N-Methyltransferase C314T Genetic Polymorphism, J. Clin. Pharmacol., 46: 408-417 (2006). PMID: 16554448
475. Lee SJ, Jusko WJ, Salaita CG, Calis KA, Jann MW, Spratlin VE, Goldstein JA, and Hon YY, Reduced Methylprednisolone Clearance Causing Prolonged Pharmacodynamics in a Healthy Subject Was Not Associated with CYP3A5*3 Allele or a Change in Diet Composition, J. Clin. Pharmacol., 46: 515-526 (2006). PMID: 16638735
476. Schwab M, Coksaygan T, Samtani MN, Jusko WJ, and Nathanielsz PW, Kinetics of Betamethasone and Fetal Cardiovascular Adverse Effects in Pregnant Sheep after Different Doses, Obstetrics & Gynecology 108: 617-625 (2006). PMID: 16946223
477. Almon RR, DuBois DC, Jin JY, Yao Z, Hazra A, Samtani M, Snyder G, Piel W, Jusko WJ, Development, Analysis, and Use of Pharmacogenomic Time Series for Pharmacokinetic/Pharmacodynamic Modeling of Multi-Tissue Polygenic Responses to Corticosteroids, In: New Research on Pharmacogenetics, ISBN 1-60021-056-2, Chapter 2, Nova Publishers (2006).
478. Krzyzanski W, Dmochowski J, Matsushima N, Jusko WJ, Assessment of Dosing Impact on Intra-Individual Variability in Estimation of Parameters for Basic Indirect Response Models, J. Pharmacokin. Pharmacodyn. 33: 635-655 (2006). PMID: 16941234
479. Meno-Tetang GML, Li H, Mis S, Pyszczynski N, Heining P, Lowe P, and Jusko WJ, Physiologically-Based Pharmacokinetic Modeling of FTY720 (2-Amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in Rats Following Oral and Intravenous Doses, Drug Met. Disp., 34: 1480-1487 (2006). PMID: 16751263
480. Hazra A, Krzyzanski W, and Jusko WJ, Mathematical Assessment of Properties of Precursor-Dependent Indirect Pharmacodynamic Response Models, J. Pharmacokin. Pharmacodyn., 33: 683-717 (2006). PMID: 17053985
481. Woo S, Krzyzanski W, and Jusko WJ, Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin after Intravenous and Subcutaneous Administration in Rats, J. Pharmacol. Exper. Ther. 319: 1297-1306 (2006). PMID: 16973883
482. Hazra A, Pyszczynski N, DuBois DC, Almon RR, and Jusko WJ, Pharmacokinetics of Methylprednisolone after Intravenous and Intramuscular Administration in Rats, Biopharm. & Drug Disp. 28: 263-273 (2007). PMID: 17569107
483. Samtani MN and Jusko WJ, Quantification of Dexamethasone and Corticosterone in Rat Biofluids and Fetal Tissue Using Highly Sensitive Analytical Methods: Assay Validation and Application to a Pharmacokinetic Study, Biomed. Chromatog. 21: 585-597 (2007). PMID: 17385808
484. Wetzler M, Earp JC, Brady MT, Keng MK, and Jusko WJ, Synergism Between Arsenic Trioxide and Heat Shock Protein 90 Inhibitors on Signal Transducer and Activator of Transcription Protein 3 Activity – Pharmacodynamic Drug-Drug Interaction Modeling, Clin. Cancer Res. 13: 2261-2270 (2007). PMID: 17404111
485. Hazra A, DuBois DC, Almon RR, and Jusko WJ, Assessing the Dynamics of Nuclear Glucocorticoid-Receptor Complex; Adding Flexibility to Gene Expression Modeling, J. Pharmacokin. Pharmacodyn., 34: 333-354 (2007). PMID: 17285360
486. Woo S and Jusko WJ, Interspecies Comparisons of Pharmacokinetics and Pharmacodynamics of Recombinant Human Erythropoietin, Drug Met. Disp. 35: 1672-1678 (2007). PMID: 17576810
487. Mager DE and Jusko WJ, Mechanistic Pharmacokinetic/Pharmacodynamic Models II, In: Pharmacometrics, The Science of Quantative Pharmacology, Ette EI & Williams PJ, Editors, Wiley & Sons, Inc, Chapter 23, pp. 607-631 (2007).

488. Jin JY and Jusko WJ, Pharmacogenomics and Pharmacokinetic/Pharmacodynamic Modeling, In: Pharmacometrics, The Science of Quantative Pharmacology, Ette EI & Williams PJ, Editors, Wiley & Sons, Inc, Chapter 19, pp. 509-528 (2007).
489. Yao Z, Zhao B, Hoffman EP, Ghimbovschi S, DuBois DB, Almon RR, and Jusko WJ, Application of a Scaling Factor in Simultaneous Modeling of Microarray Data from Diverse Chips, Pharmaceut. Res. 24: 643-649 (2007). PMID: 17318415
490. Hong Y, Mager DE, Blum RA, and Jusko WJ, Population Pharmacokinetic/Pharmacodynamic Modeling of Systemic Corticosteroid Inhibition of Whole Blood Lymphocytes: Modeling Interoccasion Pharmacodynamic Variability, Pharm. Res. 24: 1088-1097 (2007). PMID: 17385022
491. Almon RR, DuBois DC, and Jusko WJ, Microarray Analysis of the Temporal Response of Liver to Methylprednisolone: Comparative Analysis of Two Dosing Regimens, Endocrinology, 148: 2209-2225 (2007). PMID: 17303664
492. Yang E, Simcha D, Almon RR, DuBois DC, Jusko WJ, and Androulakis IP, Context Specific Transcription Factor Prediction, Ann. Biomed. Eng., 35: 1053-1067 (2007). PMID: 17377845
493. Hazra A, Pyszczynski NA, DuBois DC, Almon RR, and Jusko WJ, Modeling of Corticosteroid Effects on Hepatic Low-Density Lipoprotein Receptors and Plasma Lipid Dynamics in Rats, Pharm. Res., 25: 769-780 (2008). PMID: 17674160
494. Woo S, Krzyzanski W, and Jusko WJ, Target-mediated Pharmacokinetics and Pharmacodynamics of Recombinant Human Erythropoietin (rHuEPO), J. Pharmacokin. Pharmacodyn., 34: 849-868 (2007). PMID: 17943422
495. Yao Z, DuBois DC, Almon RR, and Jusko WJ, Pharmacokinetic/Pharmacodynamic Modeling of Corticosterone Suppression and Lymphocytopenia by Methylprednisolone in Rats, J. Pharm. Sci., 97: 2820-2832 (2008). PMID: 17828751
496. Almon RR, DuBois DC, Yao Z, Hoffman EP, Ghimbovschi S, and Jusko WJ, Microarray Analysis of the Temporal Response of Skeletal Muscle to Methylprednisolone: Comparative Analysis of Two Dosing Regimens, Physiol. Genomics 30: 282-299 (2007). PMID: 17473217
497. Hazra A, Pyszczynski NA, DuBois DC, Almon RR, and Jusko WJ, Modeling Receptor/Gene-Mediated Effects of Corticosteroids on Hepatic Tyrosine Aminotransferase Dynamics in Rats: Dual Regulation by Endogenous and Exogenous Corticosteroids, J. Pharmacokin. Pharmacodyn., 34: 643-667 (2007). PMID: 17593325
498. Woo S, Krzyzanski W, Duliege A-M, Stead RR, and Jusko WJ, Population Pharmacokinetics and Pharmacodynamics of Peptidic Erythropoiesis Receptor Agonist (ERA) in Healthy Volunteers, J. Clin. Pharmacol. 48: 43-52 (2008). PMID: 18025524
499. Hazra A, DuBois DC, Almon RR, Snyder GH, and Jusko WJ, Pharmacodynamic Modeling of Acute and Chronic Effects of Methylprednisolone on Hepatic Urea Cycle Genes in Rats, Gene Reg. Sys. Biol. 2: 1-19 (2008). PMID: 19787073
500. Woo S, Krzyzanski W, and Jusko WJ, Pharmacodynamic Model for Chemotherapy-Induced Anemia in Rats, Cancer Chem. Pharmacol., 62: 123-133 (2008). PMID: 17891399
501. Landersdorfer CB and Jusko WJ, Pharmacokinetic/Pharmacodynamic Modelling in Diabetes, Clin. Pharmacokin., 47:417-448 (2008). PMID: 18563953
502. Yang E, Almon RR, DuBois DC, Jusko WJ, and Androulakis IP, Extracting Global System Dynamics of Corticosteroid Genomic Effects in Rat Liver, J. Pharmacol. Exp. Ther. 324: 1243-1254 (2008). PMID: 18086872
503. Yao Z, Hoffman EP, Ghimbovschi S, DuBois DC, Almon RR, and Jusko WJ, Mathematical Modeling of Corticosteroid Pharmacogenomics in Rat Muscle Following Acute and Chronic Methylprednisolone Dosing, Mol. Pharm., 5: 328-339 (2008). PMID: 18271548
504. Mager DE and Jusko WJ, Development of Translational Pharmacokinetic-Pharmacodynamic Models, Clin. Pharmacol. Ther. 83: 909-912 (2008). PMID: 18388873
505. Earp JC, Pyszczynski NA, Molano DS and Jusko WJ, Pharmacokinetics of Dexamethasone in a Rat Model of Rheumatoid Arthritis, Biopharm. Drug Disp., 29: 366-372 (2008). PMID: 18613033
506. Earp JC, DuBois DC, Almon RR, and Jusko WJ, Quantitative Dynamic Models of Arthritis Progression in the Rat, Pharm. Res. 26: 196-203 (2009). PMID: 18758921
507. Yao Z, Hoffman EP, Ghimbovschi S, DuBois DC, Almon RA, and Jusko WJ, Pharmacodynamic/Pharmacogenomic Modeling of Insulin Resistant Genes in Rat Muscle after Methylprednisolone Treatment: Exploring Regulatory Signaling Cascases, Gene Reg. Sys. Biol., 2: 141-161 (2008). PMID: 19787081
508. Earp JC, DuBois DC, Molano DS, Pyszczynski NA, Keller CE, Almon RR, and Jusko WJ, Modeling Corticosteroid Effects in a Rat Model of Rheumatoid Arthritis I: Mechanistic Disease Progression Model for the Time Course of Collagen-Induced Arthritis in Lewis Rats, J. Pharmacol. Exp. Ther., 326: 532-545 (2008). PMID: 18448865
509. Earp JC, DuBois DC, Molano DS, Pyszczynski NA, Almon RR, and Jusko WJ, Modeling Corticosteroid Effects in a Rat Model of Rheumatoid Arthritis II: Mechanistic Pharmacodynamic Model for Dexamethasone Effects in Lewis Rats with Collagen-Induced Arthritis, J. Pharmacol. Exp. Ther., 326: 546-554 (2008). PMID: 18448864
510. Rohatagi S, Carrothers TJ, Jin JY, Jusko WJ, Khariton T, Walker J, Truitt K, and Salazar DE, Model-Based Development of a PPARγ Agonist, Rivoglitazone, to Aid Dose Selection and Optimize Clinical Trial Designs, J. Clin. Pharmacol. 48: 1420-1429 (2008). PMID: 18936283
511. Almon RR, Yang E, Lai W, Androulakis IP, DuBois DC, Jusko WJ, Circadian Variations in Rat Liver Gene Expression: Relationships to Drug Actions, J. Pharmcol. Exp. Ther. 326: 700-716 (2008). PMID: 18562560
512. Almon RR, Yang E, Lai W, Androulakis IP, Ghimbovschi S, Hoffman EP, Jusko WJ, and DuBois DC, Relationships Between Circadian Rhythms and Modulation of Gene Expression by Glucocorticoids in Sketetal Muscle, Am. J. Physiol. Regul. Integr. Comp. Physiol. 295: R1031-R1047 (2008). PMID: 18667713
513. Bulitta JB, Ly NS, Yang JC, Forrest A, Jusko WJ, Tsuji BT, Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa, Antimicrob. Ag. Chemother. 53: 46-56 (2009). PMID: 18852268
514. Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske A-R, Gelderblom H, Awada A, Jusko WJ: Mechanistic Population Pharmacokinetics of Total and Unbound Paclitaxel for a New Nanodroplet Formulation vs. Taxol in Cancer Patients, Cancer Chemother. Pharmacol., 63: 1049-1063 (2009). PMID: 18791718
515. Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske A-R, Gelderblom H, Awada A, Jusko WJ: Multiple-Pool Lifespan Models for Neutropenia to Assess the Population Pharmacodynamics of Unbound Paclitaxel from Two Formulations in Cancer Patients, Cancer Chemother. Pharmacol., 63: 1035-1048 (2009). PMID: 18791717
516. Landersdorfer CB, DuBois DC, Almon RR and Jusko WJ, Mechanism-Based Modeling of Nutritional and Leptin Influences on Growth in Normal and Type 2 Diabetic Rats, J. Pharmacol. Exp. Ther., 328: 644-651 (2009). PMID: 18971370
517. Mager DE, Woo S, and Jusko WJ, Scaling Pharmacodynamics from In Vitro and Preclinical Animal Studies to Humans, Drug Metab.

Pharmacokin. 24: 16-24 (2009). PMID: 19252333
518. Jin JY and Jusko WJ, Pharmacodynamics of Glucose Regulation by Methylprednisolone. I. Adrenalectomized Rats, Biopharm. Drug Disp., 30: 21-34 (2009). PMID: 19156931
519. Jin JY and Jusko WJ, Pharmacodynamics of Glucose Regulation by Methylprednisolone. II. Normal Rats, Biopharm. Drug Disp., 30: 35-48 (2009). PMID: 19156669
520. Almon RR, DuBois DC, Lai W, Xue B, Nie J and Jusko WJ, Gene Expression Analysis of Hepatic Roles in Cause and Development of Diabetes in Goto-Kakizaki Rats, J. Endocrin., 200: 331-346 (2009). PMID: 19074471
521. Cho H-Y, Blum RA, Sunderland T, Cooper GJS, and Jusko WJ, Pharmacokinetic and Pharmacodynamic Modeling of a Copper-Selective Chelator (TETA) in Healthy Adults, J. Clin. Pharmacol., 49: 916-928 (2009). PMID: 19602718
522. Yang EH, Almon RR, Dubois DC, Jusko WJ, and Androulakis IP, Identification of Global Transcriptional Dynamics, PLoS One, 4:e5992 (2009). PMID: 19593450
523. Khinkis LA, Krzyzanski W, Jusko WJ,and Greco WR, D-Optimal Designs for Parameter Estimation for Indirect Pharmacodynamic Response Models, J. Pharmacokin. Pharmacodyn. 36: 523-539 (2009). PMID: 19904585
524. Woo S, Pawaskar D, and Jusko WJ, Methods of Utilizing Baseline Values for Indirect Response Models, J. Pharmacokin. Pharmacodyn. 36: 381-405 (2009). PMID: 19697107
525. Freishtat RJ, Nagaraju K, Jusko WJ, and Hoffman EP, Glucocorticoid Efficacy in Asthma: Is Improved Tissue Remodeling Upstream of Anti-Inflammation, J. Invest. Med, 58: 19-22 (2010).
526. Wiczling P, Rosenzweig M, Vaickus L, and Jusko WJ, Pharmacokinetics and Pharmacodynamics of a Chimeric/Humanized Anti-CD3 Monoclonal Antibody, Otelixizumab (TRX4), in Subjects with Psoriasis and with Type 1 Diabetes Mellitus, J. Clin. Pharmacol. 50: 494-506 (2010). PMID: 19934031
527. Bulitta JB, Yang JC, Yohonn L, Ly NS, Brown SV, D'Hondt RE, Jusko WJ, Forrest A, Tsuji BT, Attenuation of Colistin Bactericidal Activity by High Incoulum of Pseudomonas Aeruginosa Characterized by a New Mechanism-Based Population Pharmacodynamic Model, Antimicrob Agents Chemother. 54: 2051-2062 (2010). PMID: 20211900
528. Scheff JD, Almon RR, DuBois DC, Jusko WJ, and Androulakis IP, A New Symbolic Representation for the Identification of Informative Genes in Replicated Microarray Experiments, OMICS J. Integrative Bio., 14: 239-248 (2010). PMID: 20455749
529. Nguyen TT, Almon RR, DuBois DC, Jusko WJ, and Androulakis IP, Importance of Replication in Analyzing Time-Series Gene Expression Data: Corticosteroid Dynamics and Circadian Patterns in Rat Liver, BMC Bioinformatics, 11:279 (2010). PMID: 20500897
530. Hale G, Rebello P, al Bakir I, Bolam E, Wiczling P, Jusko WJ, Vandemeulebrouchke E, Keymeulen B, Mathieu C, Ziegler A, Chatenoud L, Pipeleers D, and Waldmann H, Pharmacokinetics and Antibody Responses to a CD3 Antibody Otelixizumab Used in the Treatment of Type 1 Diabetes, J. Clin. Pharmacol. 50:1238-1248 (2010). PMID: 20147616
531. Ghoshal (Gutpa) S, Rao I, Earp JC, Jusko WJ, and Wetzler M, Down-Regulation of Heat Shock Protein 70 Improves Arsenic Trioxide and 17-DMAG Effects on Constitutive Signal Transducer and Activator of Transcription 3 Activity, Cancer Chemother. Pharmacol. 66: 681-689 (2010). PMID: 20035426
532. Findling RL, Landersdorfer CB, Kafantaris V, Pavuluri M, McNamara NK, McClellan J, Frazier JA, Sikich L, Kowatch R, Lingler J, Faber J, Taylor-Zapata P, and Jusko WJ, First-Dose Pharmacokinetics of Lithium Carbonate in Children and Adolescents, J. Clin. Psychopharm. 30: 404-410 (2010). PMID: 20531219
533. Landersdorfer CB and Jusko WJ, Pharmacokinetic/Pharmacodynamic Modeling of Glucose Clamp Effects of Inhaled and Subcutaneous Insulin in Healthy Volunteers and Diabetic Patients, Drug Met. Pharmacokin. 25:418-429 (2010). PMID: 20924141
534. Sukumaran S, Almon RR, DuBois DC, and Jusko WJ, Circadian Rhythms in Gene Expression: Relationship to Physiology, Disease, Drug Disposition and Drug Action, Adv. Drug Delivery Rev., 62: 904-917 (2010). PMID: 20542067
535. Sukumaran S, Xue B, Jusko WJ, DuBois DC, and Almon RR, Circadian Variations in Gene Expression in Rat Abdominal Adipose Tissue and Relationship to Physiology, Physiol. Genomics, 42A:141-152 (2010). PMID: 20682845
536. Ovacik MA, Sukumaran S, Almon RR, DuBois DC, Jusko WJ, and Androulakis IP, Circadian Signatures in Rat Liver: From Gene Expression to Pathways, BMC Bioinformatics, 11:540 (2010). PMID: 21040584
537. Nguyen TT, Almon RR, DuBois DC, Jusko WJ, and Androulakis IP, Comparative Analysis of Acute and Chronic Corticosteroid Pharmacogenomic Effects in Rat Liver: Transcriptional Dynamics and Regulatory Structures, BMC Bioinformatics, 11:515 (2010). PMID: 20946642
538. Gao W, Bihorel S, DuBois DC, Almon RR, and Jusko WJ, Mechanism-Based Disease Progression Modeling of Type 2 Diabetes in Goto-Kakizaki Rats , J. Pharmacokin. Pharmacodyn., 38:143-162 (2011). PMID: 21127951
539. Gao W and Jusko WJ, Pharmacokinetic and Pharmacodynamic Modeling of Exendin-4 in Type 2 Diabetic Goto-Kakizaki Rats, J. Pharmacol Exper. Ther. 336: 881-890 (2011). PMID: 21156817
540. Nie J, DuBois DC, Jusko WJ, and Almon RR, Mechanistic Population Modeling of Diabetes Disease Progression in Goto-Kakizaki Rat Muscle, Biopharm. Drug Disp., 32: 50-63 (2011). PMID: 21162119
541. Nie J, Xue B, Sukumaran S, Jusko WJ, DuBois DC, and Almon RR, Differential Muscle Gene Expression as a Function of Disease Progression in Goto-Kakizaki Diabetic Rats, Mol. Cell. Endocrin., 338: 10-17 (2011). PMID: 21356272
542. Bai JPF, Bell R, Burckart GJ, Buckman S, Eichler HG, Goodsaid FM, Fang KC, Jusko WJ, Lesko LL, Meibohm B, Patterson SD, Puig O, Smerage JB, Wagner JA, Wang J, Walton M, and Weiner R, Translational Biomarkers: From Preclinical to Clinical, A Report of 2009 AAPS/ACCP Biomarker Workshop, AAPS J, 13: 274-283 (2011). PMID: 21448748
543. Xue B, Sukumaran S, Nie J, Jusko WJ, DuBois DC, and Almon RR, Adipose Tissue Deficiency and Chronic Inflammation in Diabetic Goto-Kakizaki Rats, PLoS One, 6:e17386 (2011). PMID: 21364767
544. Scheff JD, Almon RR, DuBois DC, Jusko WJ, and Androulakis IP, Assessment of Pharmacologic Area Under the Curve when Baselines are Variable, Pharm. Res., 28: 1081-1089 (2011). PMID: 21234658
545. Lon H-K, Liu D, Zhang Q, DuBois DC, Almon RR, and Jusko WJ, Pharmacokinetic-Pharmacodynamic-Disease Progression Model for Effect of Etanercept in Lewis Rats with Collagen-Induced Arthritis, Pharm. Res. 28: 1622-1630 (2011). PMID: 21360252
546. Landersdorfer CB, He YL, Jusko WJ, Mechanism-Based Population Pharmacokinetic Modelling in Diabetes: Vildagliptin as a Tight Binding Inhibitor and Substrate of Dipeptidyl Peptidase IV, Brit. J. Clin. Pharmacol. 73: 391-401 (2012). PMID: 22442826
547. Landersdorfer CB, He YL, Jusko WJ, Mechanism-Based Population Modelling of the Effects of Vildagliptin on GLP-1, Glucose and Insulin in Patients with Type 2 Diabetes, Brit. J. Clin. Pharmacol. 73: 373-390 (2012). PMID: 22442825

548. Fang J, DuBois DC, He Y, Almon RR, and Jusko WJ, Dynamic Modeling of Methylprednisolone Effects on Body Weight and Glucose Regulation in Rats, J. Pharmacokin. Pharmacodyn. 38: 293-316 (2011). PMID: 21394487
549. Moller JB, Jusko WJ, Gao W, Hansen T, Pedersen O, Holst JJ, Overgaard RV, Madsen H, and Ingwersen SH, Mechanism-Based Population Modelling for Assessment of L-Cell Function Based on Total GLP-1 Response Following an Oral Glucose Tolerance Test, J. Pharmacokin. Pharmacodyn., 38: 713-725 (2011). PMID: 21922329
550. Sukumaran S, Jusko WJ, DuBois DC, and Almon RR, Light/Dark Oscillations in the Lung Transcriptome: Implications for Lung Homeostasis, Repair, Metabolism, Disease and Drug Action, J. Appl. Physiol. 110:1732-1747 (2011). PMID: 21436464
551. Sukumaran S, Jusko WJ, DuBois DC, and Almon RR, Mechanistic Modeling of the Effects of Glucocorticoids and Circadian Rhythms on Adipokine Expression, J. Pharmacol. Exp. Ther. 337: 734-746 (2011). PMID: 21398515
552. Cao Y, DuBois DC, Sun H, Almon RR, and Jusko WJ, Modeling Diabetes Disease Progression and Salsalate Intervention in Goto-Kakizaki Rats, J. Pharmacol. Exp. Ther. 339: 896-904 (2011). PMID: 21903749
553. Cao Y, Gao W, and Jusko WJ, Pharmacokinetic/Pharmacodynamic Modeling of GLP-1 in Healthy Rats, Pharm. Res. 29: 1078-1086 (2012). PMID: 22179928
554. Liu D, Lon H-K, DuBois DC, Almon RR, and Jusko WJ, Population Pharmacokinetic - Pharmacodynamic - Disease Progression Model for Effects of Anakinra in Lewis Rats with Collagen-Induced Arthritis, J. Pharmacokin. Pharmacodyn. 38: 769-786 (2011). PMID: 22002845
555. Gao W and Jusko WJ, Target-Mediated Pharmacokinetic and Pharmacodynamic Model of Exendin-4 in Rats, Monkeys and Man, Drug Met. Disp. 40: 990-997 (2012). PMID: 22338110
556. Gao W and Jusko WJ, Modeling Disease Progression and Rosiglitazone Intervention in Type 2 Diabetic Goto-Kakizaki Rats, J. Pharmacol. Exp. Ther. 341: 617-625 (2012). PMID: 22378938
557. Sukumaran S, DuBois DC, Jusko WJ, and Almon RR, Glucocorticoid Effects on Adiponectin Expression in Adiponectin,Vitamins & Hormones Series, ISBN: 978-0-12-398313-8, Vol. 90, Chpt 7, pp. 163-186, Elsevier Inc., Editor: G. Litwack (2012). PMID: 23017716
558. Sukumaran S, Lepist E-I, DuBois DC, Almon RR, and Jusko WJ, Pharmacokinetic/Pharmacodynamic Modeling of Methylprednisolone Effects on iNOS mRNA Expression and Nitric Oxide During LPS-Induced Inflammation in Rats, Pharm. Res. 29: 2060-2069 (2012). PMID: 22422321
559. Cao Y, DuBois DC, Almon RR, and Jusko WJ, Pharmacokinetics of Salsalate and Salicylic Acid in Normal and Diabetic Rats, Biopharm. Drug Disp., 33: 285-291 (2012). PMID: 22782506
560. Jusko WJ, Use of Pharmacokinetic Data Below Lower Limit of Quantitation Values, Pharm. Res. 29: 2628-2631 (2012). PMID: 22729370
561. Lon H-K, Liu D, and Jusko WJ, Pharmacokinetic/Pharmacodynamic Modeling in Inflammation, Crit. Rev. Biomed Eng. 40: 295-312 (2012). PMID: 23140121
562. Almon RR, DuBois DC, Sukumaran S, Wang X, Xue B, Nie J and Jusko WJ, Effects of High Fat Feeding on Liver Gene Expression in Diabetic Goto-Kakizaki Rats, Gene Regulation and Systems Biology 6: 151-168 (2012). PMID: 23236253
563. Cao Y and Jusko WJ, Applications of Minimal Physiologically-Based Pharmacokinetic Models, J. Pharmacokin. Pharmacodyn. 39: 711-723 (2012). PMID: 23179857
564. Fang J, Landersdorfer CB, Cirincione B, and Jusko WJ, Study Reanalysis Using a Mechanism-Based Pharmacokinetic/Pharmacodynamic Model of Pramlintide in Subjects with Type 1 Diabetes, AAPSJ 15: 15-29 (2013). PMID: 23054970
565. Pawaskar DK, Straubinger RM, Fetterly GJ, Ma WW, and Jusko WJ, Interactions of Everolimus and Sorafenib in Pancreatic Cancer Cells, AAPSJ 15: 78-84 (2013). PMID: 23054975
566. DuBois DC, Sukumaran S, Jusko WJ, and Almon RR, Evidence for a Glucocorticoid Receptor Beta Splice Variant in the Rat and Its Physiological Regulation in Liver, Steroids 78: 312-320 (2013). PMID: 23257260
567. Pawaskar DK, Straubinger RM, Fetterly GJ, Ma WW, and Jusko WJ, Interactions of Everolimus and Sorafenib in Whole Blood Lymphocyte Proliferation, Pharm. Res. 30: 707-713 (2013). PMID: 23151723
568. Pawaskar DK, Straubinger RM, Fetterly GJ, Hylander BH, Repasky EA, Ma WW, and Jusko WJ, Synergistic Interactions Between Sorafenib and Everolimus in Pancreatic Cancer Xenografts in Mice, Cancer Chemother. Pharmacol. 71: 1231-1240 (2013). PMID: 23455452
569. Pawaskar DK, Straubinger RM, Fetterly GJ, Hylander BH, Repasky EA, Ma WW, and Jusko WJ, Physiologically-Based Pharmacokinetic Models for Everolimus and Sorafenib in Mice, Cancer Chemother. Pharmacol. 71: 1219-1229 (2013). PMID: 23455451
570. Sorger PK, Allerheiligen SRB, Abernethy DR, Altman RB, Brouwer KLR, Califano A, D'Argenio DZ, Iyenger R, Jusko WJ, Lalonde R, Lauffenburger DA, Shoichet B, Stevens JL, Subramaniam S, Van der Graaf P, and Vicini P, Quantitative and Systems Pharmacology in the Postgenomic Era: New Approaches to Discovering and Understanding Therapeutic Drugs and Mechanisms, An NIH White Paper from the QSP Workshop Group – July, 2011, http://www.nigms.nih.gov/News/Reports/201110-syspharma.htm.
571. Liu D-Y, Lon H-K, Wang Y-L, DuBois DC, Almon RR, and Jusko WJ, Pharmacokinetics, Pharmacodynamics, and Toxicities of Methotrexate in Healthy and Collagen-induced Arthritic Rats, Biopharm. Drug Disp. 34: 203-214 (2013). PMID: 23456770
572. Jusko WJ, Moving from Basic toward Systems Pharmacodynamic Models, J. Pharm. Sci. 102: 2930-2940 (2013). PMID: 23681608
573. Cao Y, Balthasar JP, and Jusko WJ, Second-Generation Minimal Physiologically-Based Pharmacokinetic Model for Monoclonal Antibodies, J. Pharmacokin. Pharmacodyn. 40: 597-607 (2013). PMID: 23996115
574. Hamed SS, Straubinger RM, and Jusko WJ, Pharmacodynamic Modeling of Cell Cycle and Apoptotic Effects of Gemcitabine on Pancreatic Adenocarcinoma Cells, Cancer Chemother. Pharmacol. 72: 553-563 (2013). PMID: 23835677
575. Lon H-K, Liu D-Y, DuBois DC, Almon RR, and Jusko WJ, Modeling Pharmacokinetics/Pharmacodynamics of Abatacept and Disease Progression in Collagen-Induced Arthritic Rats: A Population Approach, J. Pharmacokin. Pharmacodyn. 40: 701-712 (2013). PMID: 24233383
576. Fang J, Sukumaran S, DuBois DC, Almon RR, and Jusko WJ, Meta-Modeling of Methylprednisolone Effects on Glucose Regulation in Rats, PLoS One 8: e81679 (2013). PMID: 24312573
577. Nguyen T, Almon RR, DuBois DC, Sukumaran S, Jusko WJ, and Androulakis IP, Tissue-specific Gene Expression and Regulation in Liver and Muscle following Chronic Corticosteroid Administration, Gene Reg. Sys. Biol. 8:75-87 (2014). PMID: 24653645
578. He Y, Brunstrom-Hernandez JE, Thio LL, Lackey S, Gaebler-Spira G, Kuroda MM, Stashinko E, Hoon Jr AH, Vargus-Adams J, Stevenson RD, Lowenhaupt S, McLaughlin JF, Christensen A, Dosa NP, Butler M, Schwabe A, Lopez C, Roge D, Kennedy D, Tilton A, Krach LE, Lewandowski A, Dai H, Gaedigk A, Leeder JS, and Jusko WJ, Population Pharmacokinetics of Oral Baclofen in Pediatric Patients with Cerebral Palsy, J. Peds. 164: 1181-1188 (2014). PMID: 24607242
579. Cao Y and Jusko WJ, Survey of Monoclonal Antibody Disposition in Man Utilizing a Minimal Physiologically-Based Pharmacokinetic

Model, J. Pharmacokin. Pharmacodyn. 41: 571-580 (2014). PMID: 25146360

580. Grimsrud KN, Ait-Oudhia S, Durbin-Johnson BP, Rocke DM, Mama KR, Rezende ML, Stanley SD, and Jusko WJ, Pharmacokinetic and Pharmacodynamic Analysis Comparing Diverse Effects of Detomidine, Medetomidine and Dexmedetomidine in the Horse: A Population Analysis, J. Vet. Pharmacol. Ther. 38: 24-34 (2014). PMID: 25073816
581. Nouri-Nigjeh E, Sukumaran S, Tu C, Li J, Yu H, Duan X, DuBois DC, Almon RR, Jusko WJ and Qu J, Highly Multiplexed and Reproducible Ion Current-Based Strategy for Large-Scale Quantitative Proteomics with Application to Protein Expression Dynamics Induced by Methylprednisolone in 60 Animals, Analytical Chem. 86: 8149-8157 (2014). PMID: 25072516
582. Wang X, DuBois DC, Sukumaran S, Ayyar V, Jusko WJ, and Almon RR, Diabetes disease progression in Goto-Kakizaki rats: effects of salsalate treatment, Diabetes Metab. Syndr. Obes.: Targets and Therapy 7: 381-389 (2014). PMID: 25120374
583. Cao Y and Jusko WJ, Incorporating Target-Mediated Drug Disposition in a Minimal Physiologically-Based Pharmacokinetic Model for Monoclonal Antibodies, J. Pharmacokin. Pharmacodyn. 41: 375-387 (2014). PMID: 25077917
584. Wang X, DuBois DC, Sukumaran S, Ayyar V, Jusko WJ, and Almon RR, Variability in Zucker Diabetic Fatty Rats: Differences in Disease Progression in Hyperglycemic and Normoglycemic Animals, Diabetes Metab. Syndr. Obes.: Targets and Therapy 7: 531-541 (2014). PMID: 25419150
585. Kamisoglu K, Sukumaran S, Nouri-Nigjeh E, Tu C, Li J, Shen X, Duan X, Qu J, Almon RR, DuBois DC, Jusko WJ, and Androulakis IP, Tandem Analysis of Transcriptome and Proteome Changes after a Single Dose of Corticosteroid: A System Approach to Liver Function in Pharmacogenomics, OMICS J. Integrative Bio. 19: 80-91 (2015). PMID: 25611119
586. Ayyar V, Almon RR, Jusko WJ, and DuBois DC, Quantitative Tissue-Specific Dynamics of In Vivo GILZ mRNA Expression and Regulation by Endogenous and Exogenous Glucocorticoids, Physiol Rep. 3(6):e12382 (2015). PMID: 26056061
587. Chen X, DuBois DC, Almon RR, and Jusko WJ, Biodistribution of Etanercept to Tissues and Sites of Inflammation in Arthritic Rats, Drug Met. Disp. 43:898-907 (2015). PMID: 25834031
588. Zhao J, Cao Y, and Jusko WJ, Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model, Pharm. Res. 32: 3269-3281 (2015). PMID: 25939552
589. Xue B, Nie J, Wang X, DuBois DC, Jusko WJ and Almon RR, Effects of High Fat Feeding on Adipose Tissue Gene Expression in Diabetic Goto-Kakizaki Rats, Gene Reg. Sys. Bio. 9: 15-26 (2015). PMID: 26309393
590. Lon HK, DuBois DC, Earp JC, Almon RR and Jusko WJ, Modeling Effects of Dexamethasone on Disease Progression of Bone Mineral Density in Collagen-Induced Arthritic Rats, Pharmacol. Res. Perspect., 3(5):e00169 (2015). PMID: 26516581
591. Yoo H, Iirola T, Vilo S, Manner T, Aantaa R, Lahtinen M, Scheinin M, Jusko WJ, and Olkkola KT, Mechanism-Based Population Pharmacokinetic and Pharmacodynamic Modeling of Intravenous and Intranasal Dexmedetomidine in Healthy Subjects, Eur. J. Clin. Pharmacol. 71: 1197-1207, (2015). PMID: 26233335
592. Estepp JH, Melloni C, Thornburg CD, Wiczling P, Rogers Z, Rothman JA, Green NS, Liem R, Brandow AM, Crary SE, Howard TH, Morris MH, Lewandowski A, Garg U, Jusko WJ, and Neville KA, on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network Administrative Core Committee, Pharmacokinetics and Bioequivalence of a Liquid Formulation of Hydroxyurea in Children with Sickle Cell Anemia, Blood, J. Clin. Pharmacol. 56: 298-306 (2016). PMID: 26201504
593. Zhu X, Straubinger RM, and Jusko WJ, Mechanism-Based Mathematical Modeling of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells, J. Pharmacokin. Pharmacodyn. 42: 477-496 (2015). PMID: 26252969
594. Miao X, Koch G, Straubinger RM, and Jusko WJ, Pharmacodynamic Modeling of Combined Chemotherapeutic Effects Predicts Synergistic Activity of Gemcitabine and Trabectedin in Pancreatic Cancer Cells, Cancer Chemother. Pharmacol. 77: 181-193 (2016). PMID: 26604207
595. Fung H-L and Jusko WJ, Perspectives on the History and Scientific Contributions of Gerhard Levy, J. Pharmacokin. Pharmacodyn. 42:429–446 (2015). PMID: 26403702
596. Cao Y and Jusko WJ, Mechanistic Physiologically Based Pharmacokinetic Models in Development of Therapeutic Monoclonal Antibodies in: ADME and Translational PK/PD of Therapeutic Proteins, ISBN: 978-1-118-89864-2, Chpt 12, pp. 159-174, John Wiley & Sons, Inc., New Jersey, Editors: H. Zhou & F.P. Theil (2015).
597. Rao R, DuBois DC, Almon RR, Jusko WJ, and Androulakis I, Mathematical Modeling of the Circadian Dynamics of the Neuroendocrine-Immune Network in Experimentally Induced Arthritis, Am. J. Physiol. Endocrinol. Metab. 311:E310-24 (2016). PMID: 27221115
598. Chen X, Jiang X, Jusko WJ, Zhou H, and Wang W, Minimal Physiologically-Based Pharmacokinetic (mPBPK) Model for a Monoclonal Antibody against Interleukin-6 in Mice with Collagen-Induced Arthritis, J. Pharmacokin. Pharmacodyn. 43:291-304 (2016). PMID: 27119518
599. Koch G, Schropp J, and Jusko WJ, Assessment of Non-linear Combination Effect Terms for Drug-Drug Interactions, J. Pharmacokin. Pharmacodyn. 43: 461-479 (2016). PMID: 27638639
600. Jusko WJ, Perspectives on Variability in Pharmacokinetics of an Oral Contraceptive Product, Contraception, 95: 5-9 (2017). PMID: 27475034
601. Jusko WJ, Clarification of Contraceptive Drug Pharmacokinetics in Obesity, Contraception, 95: 10-16 (2017). PMID: 27542520
602. Miao X, Koch G, Ait-Oudhia S, Straubinger RM, and Jusko WJ, Pharmacodynamic Modeling of Cell Cycle Effects of Drug Combinations in Pancreatic Cancer Cells: Analysis of Gemcitabine and Trabectedin Interactions, Front. Pharmacol. http://dx.doi.org/10.3389/fphar.2016.00421 7: Article 421: 1-16 (2016). PMID: 27895579
603. Jusko WJ, Foundations of Pharmacodynamic Systems Analysis, In: Systems Pharmacology and Pharmacodynamics, AAPS Advances in the Pharmaceutical Sciences Series 23, ISBN: 978-3-319-44534-2, Chap. 8, pp. 161-175, Springer, NY, Editors: DM Mager and H Kimko (2016).
604. Koch G, Jusko WJ, and Schropp J, Target-Mediated Drug Disposition with Drug-Drug Interaction, Part I: Single Drug Case in Alternative Formulations, J. Pharmacokin. Pharmacodyn., 44:17-26 (2017). PMID: 28074395
605. Koch G, Jusko WJ, and Schropp J, Target-Mediated Drug Disposition with Drug-Drug Interaction, Part II: Competitive and Uncompetitive Cases, J. Pharmacokin. Pharmacodyn., 44:27-42 (2017). PMID: 28074396
606. Vali P, Chandrasekharan P, Rawat M, Gugino S, Koenigsknecht C, Helman J, Jusko WJ, Wyckoff MH, Mathew B, Berkelhamer S, Nair J, and Lakshminrusimha S, Evaluation of Timing and Route of Epinephrine in a Neonatal Model of Asphyxial Arrest, J. Amer. Heart Assoc., Feb 18;6(2) (2017). PMID: 28214793
607. Kamisoglu K, Acevedo A, Almon RR, Coyle S, Corbett S, DuBois DC, Nguyen TT, Jusko WJ, and Androulakis IP, Understanding Physiology in the Continuum: Integration of Information from Multiple *-omics* Levels, Front. Pharmacol. https://doi.org/10.3389/fphar.2017.00091 8: Article 91: 1-19 (2017). PMID: 28289389

608. Ayyar VS, Almon RR, DuBois DC, Sukumaran S, Qu J, and Jusko WJ, Functional Proteomic Analysis of Corticosteroid Pharmacodynamics in Rat Liver: Relationship to Hepatic Stress, Signaling, Energy Regulation, and Drug Metabolism, J. Proteomics http://dx.doi.org/10.1016/j.jprot.2017.03.007 160:84-105 (2017). PMID: 28315483
609. Li X, DuBois DC, Almon RR, and Jusko WJ, Effect of Disease-Related Changes in Plasma Albumin on the Pharmacokinetics of Naproxen in Male and Female Arthritic Rats, Drug Metab. Disp. 45: 476-483 (2017). PMID: 28246126
610. Li X, DuBois DC, Almon RR, and Jusko WJ, Modeling Sex Differences in Pharmacokinetics, Pharmacodynamics, and Disease Progression Effects of Naproxen in Rats with Collagen-Induced Arthritis, Drug Metab. Disp. 45:484-491 (2017). PMID: 28246127
611. Chen X, DuBois DC, Almon RR, and Jusko WJ, Characterization and Interspecies Scaling of rhTNF-α Pharmacokinetics with Minimal Physiologically-Based Pharmacokinetic (mPBPK) Models, Drug Metab. Disp. 45:798-806 (2017). PMID: 28411279
612. Chen X, DuBois DC, Almon RR, and Jusko WJ, Interrelationships between Infliximab and rhTNF-α in Plasma using Minimal Physiologically-Based Pharmacokinetic (mPBPK) Models, Drug Metab. Disp. 45:790-797 (2017). PMID: 28411280
613. Li X, DuBois DC, Song D, Almon RR, Jusko WJ and Chen X, Modeling Combined Immunosuppressive and Anti-inflammatory Effects of Dexamethasone and Naproxen in Rats Predicts the Steroid-Sparing Potential of Naproxen, Drug Metab. Disp. 45:834-845 (2017). PMID: 28416614
614. Nie J, DuBois DC, Xue B, Jusko WJ and Almon RR, Effects of High Fat Feeding on Skeletal Muscle Gene Expression in Diabetic Goto-Kakizaki Rats, Gene Reg. Syst. Biol. 11: 1-11 (2017). PMID: 28607540
615. Ayyar VS, DuBois DC, Almon RR, and Jusko WJ, Mechanistic Multi-Tissue Modeling of Glucocorticoid-Induced Leucine Zipper Regulation: Integrating Circadian Gene Expression with Receptor-Mediated Corticosteroid Pharmacodynamics, J. Pharmacol. Exp. Ther. 363:45-57 (2017). PMID: 28729456
616. McLaughlin MJ, He Y, Brunstrom-Hernandez J, Thio LL, Carleton BC, Ross CJD, Gaedigk A, Lewandowski A, Dai H, Jusko WJ, and Leeder JS, Pharmacogenomic Variability of Oral Baclofen Clearance and Clinical Response in Children with Cerebral Palsy, PM&R 10: 235-244 (2018). PMID: 28867665
617. Zhu X, Shen X, Qu J, Straubinger RM, and Jusko WJ, Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer, Front. Pharmacol. https://doi.org/10.3389/fphar.2018.00084 9: Article 84: 1-14 (2018). PMID: 29520231
618. Chen X, Jiang X, Doddareddy R, Geist B, McIntosh T, Jusko WJ, Zhou H, and Wang W, Development and Translational Application of a Minimal Physiologically-Based Pharmacokinetic (mPBPK) Model for a Monoclonal Antibody (mAb) Against Interleukin 23 (IL-23) in IL-23-Induced Psoriasis-Like (PsL) Mice, J. Pharmacol. Exp Ther. 365:140-155 (2018). PMID: 29420255
619. Ayyar V, Sukumaran S, DuBois DC, Almon RR, Qu J, and Jusko WJ, Receptor/Gene/Protein-Mediated Signaling Connects Methylprednisolone Exposure to Metabolic and Immune-Related Pharmacodynamic Actions in Liver, J. Pharmacokin. Pharmacodyn. doi: 10.1007/s10928-018-9585-x, 45: 557-575 (2018). PMID: 29704219
620. Mavroudis PD, DuBois DC, Almon RR and Jusko WJ, Daily Variation of Gene Expression in Diverse Rat Tissues, PLoS One, 13: e0197258 (2018). PMID: 29746605
621. Mavroudis PD, DuBois DC, Almon RR and Jusko WJ, Modeling Circadian Variability of Core-Clock and Clock-Controlled Genes in Four Tissues of the Rat, PLoS One, 13: e0197534 (2018). PMID: 29894471
622. Molins EAG and Jusko WJ, Assessment of Three-Drug Combination Pharmacodynamic Interactions in Pancreatic Cancer Cells, AAPS J 20:80 doi: 10.1208/s12248-018-0235-4 (2018). PMID: 29951754
623. Zhu X, Shen X, Qu J, Straubinger RM, and Jusko WJ, Multi-Scale Network Model Supported by Proteomics Data for Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells, CPT:PSP 7: 549-561 (2018). PMID: 30084546
624. Li X, Jusko WJ and Cao Y, Role of Interstitial Fluid Turnover on Target Suppression by Therapeutic Biologics Using a Minimal Physiologically-based Pharmacokinetic (mPBPK) Model, J. Pharmacol. Exp. Ther. 367: 1-8 (2018). PMID: 30002096
625. Zhu X, Trueman S, Straubinger RM, and Jusko WJ, Physiologically-Based Pharmacokinetic and Pharmacodynamic Models for Gemcitabine and Birinapant in Pancreatic Cancer Xenografts, J. Pharmacokin. Pharmacodyn. 45: 733-746 (2018). PMID: 30069744
626. Ayyar V, Sukumaran S, DuBois DC, Almon RR, and Jusko WJ, Modeling Corticosteroid Pharmacogenomics and Proteomics in Rat Liver, , J. Pharmacol. Exp. Ther. 367: 168-183 (2018). PMID: 30087156
627. Conklin LS, Damsker JM, Hoffman EP, Jusko WJ, Mavriodis P, Schwartz BD, Mengle-Gaw LJ, Smith EC, Mah JK, Guglieri M, Nevo Y, Kuntz N, McDonald CM, Tulinius M, Ryan M, Webster R, Castro D, Finkel RS, Smith AL, Morgenroth LP, Arrieta A, Shimony M, Jaros M, Shale P, McCall JM, Hathout Y, Nagaraju K, van den Anker J, Ward LM, Ahmet A, Cornish MR, and Clemens PR, Phase IIa Trial in Duchenne Muscular Dystrophy Shows Vamorolone is a First-in-class Dissociative Steroidal Anti-inflammatory Drug, Pharmacol. Res. 136: 140-150 (2018). PMID: 30219580
628. Song D, DuBois DC, Almon RR, and Jusko WJ, Modeling Sex Differences in Anti-inflammatory Effects of Dexamethasone in CIA Rats, Pharm. Res. 35: 203 (2018). PMID: 30191329
629. Mavroudis PD, van den Anker J, Conklin LS, Damsker JM, Hoffman EP, Nagaraju K, Clemens PR, and Jusko WJ, Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys with Duchenne Muscular Dystrophy, J Clin. Pharmacol., On Line First (2019). PMID: 30742306
630. Ayyar VS, Krzyzanski W, and JuskoWJ, Indirect Pharmacodynamic Models for Responses with Circadian Removal, J. Pharmacokin. Pharmacodyn., 46: 89-101 (2019). PMID: 30694437
631. Luo D, Westhoff CL, Edelman AB, Natavio M, Stanczyk FZ, and Jusko WJ, Altered Pharmacokinetics of Combined Oral Contraceptives in Obesity – Multi-Study Assessment, Contraception, 99: 256-263 (2019). PMID: 30684471
632. Luo D, Carter K, He, X, Jusko, W, and Lovell, J, Pharmacokinetics and Pharmacodynamics of Liposomal Chemophototherapy with Short Drug-Light Intervals, J. Control. Rel., 297: 39-47 (2019). PMID: 30684512
633. Natavio M, Stanczyk FZ, Molins EA, Nelson AL, and Jusko WJ, Pharmacokinetics of the 1.5 mg Levonorgestrel Emergency Contraceptive in Women with Normal, Obese and Extremely Obese Body Mass Index, Contraception, 99: 306-311 (2019). PMID: 30703352
634. Acevedo A, Berthel A, DuBois D, Almon RR, Jusko WJ, and Androulakis IP, Pathway-Based Analysis of the Liver Response to Intravenous Methylprednisolone Administration in Rats: Acute Versus Chronic Dosing. Gene Regul. Syst. Bio., 13: 1–20 (2019). PMID: 31019365
635. Ayyar VS, Song D, DuBois DC, Almon RR, Jusko WJ, Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics – I: Determination and Prediction of Dexamethasone and Methylprednisolone Tissue Binding in the Rat, J. Pharmacol. Exp. Ther., 370: 318-326 (2019). PMID: 31197020
636. Ayyar VS, DuBois DC, Nakamura T, Almon RR, and Jusko WJ, Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics – II:

Sex Differences in Methylprednisolone Pharmacokinetics and Corticosterone Suppression, J. Pharmacol. Exp. Ther., 370:327-336 (2019). PMID: 31197019

637. Ayyar VS, DuBois DC, Almon RR, and Jusko WJ, Modeling Corticosteroid Pharmacokinetics & Pharmacodynamics – III: Estrous Cycle- and Estrogen Receptor-Dependent Antagonism of GILZ Enhancement by Corticosteroids, J. Pharmacol. Exp. Ther., 370: 337-349 (2019). PMID: 31197018
638. Barcellos T, Natavio M, Stanczyk FZ, Luo D, Jusko WJ, and Bender NM, Effects of Ritonavir-Boosted Protease Inhibitors on Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics in HIV-Positive Women, Contraception, 100:2 83-287 (2019). PMID: 31194965
639. Mavroudis PD, Ayyar VS, and Jusko WJ, ATLAS mPBPK: a MATLAb-based Tool for Modeling and Simulation of Minimal Physiologically Based Pharmacokinetic Models, CPT:PSP, 8: 557-566 (2019). PMID: 31154668
640. Yu R, Song D, DuBois DC, Almon RR, and Jusko WJ, Modeling Combined Anti-Inflammatory Effects of Dexamethasone and Tofacitinib in Arthritic Rats, AAPS J 21: 93 (pp. 1-9) (2019). PMID: 31342216
641. Jusko WJ, Journal Editor's Final Report, J. Pharmacokin. Pharmacodyn., 46: 511-512 (2019). PMID: 31720983
642. Jobe AH, Milad MA, Peppard T, and Jusko WJ, Pharmacokinetics and Pharmacodynamics of Intramuscular and Oral Betamethasone and Dexamethasone in Reproductive Age Women in India, Clin Transl Sci. 13: 391-399 (2020). PMID: 31808984
643. Ayyar VS and Jusko WJ, Transitioning from Basic Towards Systems Pharmacodynamic Models: Lessons from Corticosteroids, Pharmacol. Rev., 72: 414-438 (2020). PMID: 32123034
644. Yu R, Li X, DuBois DC, Almon RR, Cao Y, and Jusko WJ, Interactions of Tofacitinib and Dexamethasone on Lymphocyte Proliferation, Pharm. Res., 37: 105 (2020). PMID: 32458079
645. Li X, Conklin LS, van den Anker J, Hoffman EP, Clemens PR, and Jusko WJ, Exposure-Response Analysis of Vamorolone (VBP15) in Boys with Duchenne Muscular Dystrophy, J Clin. Pharm. 60: 1385-1396 (2020). PMID: 32434278
646. Acevedo A, Dubois D, Almon RR, Jusko WJ, and Androulakis IP, Modeling Pathway Dynamics of the Skeletal Muscle Response to Intravenous Methylprednisolone (MPL) Administration in Rats: Dosing and Tissue Effects, Frontiers in Bioengineering and Biotechnology, *Special Issue* on *Biol. Control Systems and Disease Modeling* 8: Article 759: 1-18, DOI=10.3389/fbioe.2020.00759; https://www.frontiersin.org/article/10.3389/fbioe.2020.00759 (2020). PMID: 32760706
647. Chen X, Song D, Nakada S, Qiu J, Iwamoto K, Chen RH, Lim YP, Jusko WJ, and Stonestreet BS, Pharmacokinetics of Inter-Alpha Inhibitor Proteins and Effects on Hemostasis after Hypoxic-Ischemic Brain Injury in Neonatal Rats., Curr. Pharm. Des. 26: 1-10 (2020). PMID: 32316887
648. Ramanadhan S, Jusko WJ, and Edelman A, Pharmacokinetics of Hormonal Contraception in Individuals with Obesity: a Review, Curr. Obstet. Gynecol. Rep., 9: 72-78 (2020). PMID: 33117601
649. Song D, Sun L, DuBois DC, Almon RR, Meng S, and Jusko WJ, Physiologically-Based Pharmacokinetics of Dexamethasone in Rats, Drug Metab. Disp., 48: 811-818 (2020). PMID: 32601175
650. Elmeliegy M, Den Haese J, Talati C, Wetzler M, and Jusko WJ, Towards Better Combination Regimens of Cytarabine and FLT3 Inhibitors in Acute Myeloid Leukemia, Cancer Chemother. Pharmacol. 86: 325-337 (2020). PMID: 32748108
651. Li X, DuBois DC, Almon RR, and Jusko WJ, Physiologically-Based Pharmacokinetic Modeling Involving Nonlinear Plasma and Tissue Binding: Application to Prednisolone and Prednisone in Rats, J. Pharmacol. Exp. Ther., 375: 385-396 (2020). PMID: 32883831
652. Jusko WJ, Molins EAG, and Ayyar VS, Seeking Nonspecific Binding: Assessing the Reliability of Tissue Dilutions for Calculating Fraction Unbound, Drug Metab. Disp., 48: 894-902 (2020). PMID: 32759367
653. Liu X and Jusko WJ, Physiologically-Based Pharmacokinetics of Lysosomotropic Chloroquine in Rat and Man, J. Pharmacol. Exp. Ther., 376: 261- 272 (2020). PMID: 33277347
654. Krzyzanski W, Milad MA, Jobe AH, Peppard T, Bies RR, and Jusko WJ, Population Pharmacokinetic Modeling of Intramuscular and Oral Dexamethasone and Betamethasone in Indian Women, J. Pharmacokin. Pharmacodyn., 48: 261-272 (2021). PMID: 33389521
655. Song D and Jusko WJ, Across-Species Meta-Analysis of Dexamethasone Pharmacokinetics Utilizing Three Allometric Modeling Approaches, Biopharm. Drug Disp., 42: 191-203 (2021). PMID: 33638217
656. Krzyzanski W, Milad MA, Jobe AH, Peppard T, Bies RR, and Jusko WJ, Population Pharmacodynamic Modeling of Intramuscular and Oral Dexamethasone and Betamethasone Effects on Six Biomarkers with Circadian Complexities in Indian Women, J. Pharmacokin. Pharmacodyn., 48: 411-438 (2021). PMID: 33954911
657. Mavroudis P and Jusko WJ, Mathematical Modeling of Mammalian Circadian Clocks Affecting Drug and Disease Responses, J. Pharmacokin. Pharmacodyn., 48: 375-386 (2021). PMID: 33725238
658. Acevedo A, Mavroudis P, Dubois D, Almon RR, Jusko WJ, and Androulakis IP, Pathway-Level Analysis of Genome-wide Circadian Dynamics in Diverse Tissues in Rat and Mouse, J. Pharmacokin. Pharmacodyn., 48: 361-374 (2021). PMID: 33768484
659. Lin Q, Qian Z, Mager D, Jusko WJ, Ma WW, and Straubinger RM, Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation, J. Pharmacol. Exp. Ther., 377: 370-384 (2021). PMID: 33753538
660. Jeong YS and Jusko WJ, Meta-Assessment of Metformin Absorption and Disposition Pharmacokinetics in Nine Species, Pharmaceuticals, 14(6): Article 545; https://doi.org/10.3390/ph14060545 (2021). PMID: 34200427
661. Pawaskar D, Chen X, Glassman F, May F, Roberts A, Biondo M, McKenzie A, Nolte MW, Jusko WJ, and Tortorici M, Pharmacokinetic/Pharmacodynamic Modeling for Dose Selection in a First-in-Human Trial of Activated Factor XII Inhibitor Garadacimab (CSL312), Clin. Transl. Sci., 15:709–720. (2022). PMID: 34811931
662. Jusko WJ and Li X, Assessment of the Kochak-Benet Equation for Hepatic Clearance for the Parallel-Tube Model: Relevance of Classic Clearance Concepts in PK and PBPK. AAPS J 24: 5 https://doi.org/10.1208/s12248-021-00656-z (2022). PMID: 34853928
663. Swierczek A, Pomierny B, Wyska E, and Jusko WJ, Pharmacokinetic/Pharmacodynamic Assessment of Selective Phosphodiesterase Inhibitors in a Mouse Model of Autoimmune Hepatitis, J. Pharmacol. Exp. Ther., 381:151–163 (2022). PMID: 35221290
664. Jeong Y-S and Jusko WJ, Consideration of Fractional Distribution Parameter f_d in the Chen and Gross Method for Tissue-to-Plasma Partition Coefficients: Comparison of Several Methods, Pharm. Res., 39:463-479 (2022). PMID: 35288804
665. Ren T, Zhu X, Jusko NM, Krzyzanski W, and Jusko WJ, Pharmacodynamic Model of Slow Reversible Binding and Its Applications in Pharmacokinetic/Pharmacodynamic Modeling: Review and Tutorial, J. Pharmacokin. Pharmacodyn., 49: 493-510 (2022). PMID: 36040645
666. Jeong Y-S and Jusko WJ, Determinants of Biological Half-Lives and Terminal Slopes in Physiologically-Based Pharmacokinetic Systems:

Assessment of Limiting Conditions, AAPS J. 24:96 (2022). PMID: 36042121

667. Li X and Jusko WJ, Assessing Liver-to-Plasma Partition Coefficients and In Silico Calculation Methods: When Does the Hepatic Model Matter in PBPK?, Drug Metab. Disp. 50:1501-1512, doi: 10.1124/dmd.122.000994 (2022). PMID: 36195337

668. Lin Q, Shen S, Qian Z, Rasam SS, Jusko WJ, Kandel ES, Qu J, and Straubinger RM, Comparative Proteomic Analysis Identifies Key Metabolic Regulators of Gemcitabine Resistance in Pancreatic Cancer, Mol. Cell Proteomics 21(10):100409. doi: 10.1016/j.mcpro.2022.100409 (2022). PMID: 36084875

669. Swierczek A and Jusko WJ, Pharmacokinetic/Pharmacodynamic Modeling of Dexamethasone Anti-Inflammatory and Immunomodulatory Effects in LPS-Challenged Rats: A Model for Cytokine Release Syndrome, J. Pharmacol. Exp. Ther., 384: 455-472 (2023). PMID: 36631280

670. Krzyzanski W, Milad MA, Jobe AH, and Jusko WJ, Minimal Physiologically-Based Hybrid Model of Pharmacokinetics in Pregnant Women: Application to Antenatal Corticosteroids, CPT:PSP, Accepted (2023).

671. Li X and Jusko WJ, Exploring the Pharmacokinetic Mysteries of the Liver: Application of Series-Compartment Models of Hepatic Elimination, Drug Metab. Disp., *On-Line-First* (2023). PMID: 36732075

672. Jeong Y-S and Jusko WJ, Theoretical Examination Seeking a Tangible Physical Meaning of Slopes and Intercepts of the Plasma Concentration-Time Relationships in Minimal Physiologically Based Pharmacokinetic Models, AAPS J. 25(1):19. doi: 10.1208/s12248-022-00779-x (2022). PMID: 36702940